<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1709245927
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Sapropterin Amarox
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SAPROPTERIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        13068
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="M/s Annora Pharma Private Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            M/s Annora Pharma Private Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A16AX07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>apropterin Amarox contains three active substance sapropterin &nbsp;which &nbsp;is &nbsp;a &nbsp;synthetic &nbsp;copy &nbsp;of a &nbsp;body&rsquo;s &nbsp;own &nbsp;substance cal ed tetrahydrobiopterin (BH4). BH4 is required by the body to &nbsp;use an amino acid cal ed phenylalanine in order to build another amino acid cal ed tyrosine.&nbsp;<br />Sapropterin Amarox is used to treat hyperphenylalaninaemia (HPA) or &nbsp;phenylketonuria &nbsp;(PKU) &nbsp;in &nbsp;patients &nbsp;of &nbsp;al &nbsp;ages. &nbsp;HPA and PKU are due to abnormal y high levels of &nbsp;phenylalanine in the blood which can be harmful. Sapropterin Amarox reduces these levels in some patients who respond to BH4 and can help increase the amount of phenylalanine that can be included in the diet.&nbsp;<br />This medicine is also used to treat an inherited disease &nbsp;cal ed &nbsp;BH4 &nbsp;deficiency &nbsp;in &nbsp;patients &nbsp;of al &nbsp;ages, &nbsp;in &nbsp;which the body cannot &nbsp;produce &nbsp;enough &nbsp;BH4. &nbsp;Because &nbsp;of &nbsp;very &nbsp;low &nbsp;BH4 &nbsp;Levels &nbsp;phenylalanine is not &nbsp;used properly and its levels rise, resulting in harmful effects. By replacing the BH4 that the body cannot&nbsp;produce, Sapropterin Amarox reduces the harmful excess of &nbsp;phenylalanine &nbsp;in &nbsp;the &nbsp;blood &nbsp;and &nbsp;increases &nbsp;the &nbsp;dietary &nbsp;tolerance to phenylalanine.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>apropterin Amarox Do<br />not take Sapropterin<br />Amarox<br />If you are al ergic to sapropterin or any of the other ingredients of this medicine (listed in section 6).<br />Warnings and precautions&nbsp;<br />Talk to your doctor or pharmacist before taking Sapropterin Amarox, particularly:&nbsp;</p><p>&bull;&nbsp;&nbsp; &nbsp;If you are 65 years of age or older<br />&bull;&nbsp;&nbsp; &nbsp;if you have problems with your kidney or liver<br />&bull;&nbsp;&nbsp; &nbsp;if you are il . Consultation &nbsp; with &nbsp; a physician &nbsp; is recommended during &nbsp; il ness as blood phenylalanine levels may increase<br />&bull;&nbsp;&nbsp; &nbsp;if you have predisposition to convulsions</p><p>When you are treated &nbsp; with &nbsp;Sapropterin Amarox, &nbsp;your &nbsp;doctor &nbsp;wil &nbsp;test &nbsp;your &nbsp;blood &nbsp;to &nbsp;verify &nbsp;how &nbsp;much &nbsp;phenylalanine and tyrosine it contains and may decide to adjust the dose of Sapropterin Amarox or your diet if needed.&nbsp;<br />You must continue your &nbsp;diet &nbsp;treatment &nbsp;as &nbsp;recommended &nbsp;by &nbsp;your &nbsp;doctor. &nbsp;Do &nbsp;not &nbsp;change &nbsp;your &nbsp;diet without contacting your doctor. Even if you take Sapropterin Amarox, if your phenylalanine blood levels are not wel controlled, you can develop severe &nbsp;neurologic &nbsp;problerns.Your &nbsp;doctor &nbsp;should &nbsp;continue &nbsp;to &nbsp;monitor &nbsp;your blood phenylalanine levels often during your treatment with Sapropterin Amarox, to make sure &nbsp;that &nbsp;your &nbsp;blood phenylalanine levels are not too high or too low.&nbsp;<br />Other medicines and Sapropterin Amarox&nbsp;<br />Tel your &nbsp;doctor &nbsp;or pharmacist &nbsp;if &nbsp;you are &nbsp;taking, &nbsp;have &nbsp;recently &nbsp;taken or might &nbsp;take &nbsp;any other &nbsp;medicines. &nbsp;In particular you should tel your doctor if you are using:&nbsp;</p><p>&bull;&nbsp;&nbsp; &nbsp;levodopa (used to treat Parkinson&#39;s disease)<br />&bull;&nbsp;&nbsp; &nbsp;medicines for treatment of cancer (e.g. methotrexate).</p><p>&bull;&nbsp;&nbsp; &nbsp;medicines&nbsp;for treatment of bacterial infections (e.g. trimethoprim).<br />&bull;&nbsp;&nbsp; &nbsp;medicines&nbsp;that cause dilation of blood vessels (such as glyceryl trinitrate&nbsp;(GTN), isosorbide dinitrate (ISDN), sodium nitroprusside (SNP), molsidomin, minoxidil).</p><p>Pregnancy and breast-feeding&nbsp;<br />If you are pregnant or breast-feeding, think you &nbsp;may &nbsp;be &nbsp;pregnant &nbsp;or &nbsp;are &nbsp;planning &nbsp;to &nbsp;have &nbsp;a &nbsp;baby, &nbsp;ask your doctor or pharmacist for advice before taking this medicine.&nbsp;<br />If you are pregnant your doctor &nbsp;wil &nbsp;tel &nbsp;you &nbsp;how &nbsp;to &nbsp;control phenylalanine &nbsp;levels &nbsp;adequately. &nbsp;If these &nbsp;are not strictly controlled before or when you become pregnant, this &nbsp;could &nbsp;be &nbsp;harmful to you and your baby. Your doctor wil monitor the restriction of dietary phenylalanine intake prior and during pregnancy.&nbsp;<br />If the strict diet &nbsp;does &nbsp;not &nbsp;adequately &nbsp;reduce &nbsp; phenylalanine &nbsp;amount &nbsp;in &nbsp;your &nbsp;blood &nbsp;your &nbsp;doctor &nbsp;wil consider whether you must take this medicine.&nbsp;<br />You should not take this medicine if you are breast-feeding.&nbsp;<br />Driving and using machines&nbsp;<br />Sapropterin Amarox is not expected to affect the ability to drive and use machines.&nbsp;<br />Sapropterin Amarox contains sodium&nbsp;<br />This medicine contains less than 1 mmol sodium (23 mg) &nbsp;per &nbsp;tablet, &nbsp;that &nbsp;is &nbsp;to &nbsp;say &nbsp;essential y &nbsp;&lsquo;sodium- &nbsp;free&rsquo;.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told &nbsp;you. &nbsp;Check &nbsp;with &nbsp;your &nbsp;doctor if &nbsp;you are &nbsp;not sure.<br />Dosing for PKU<br />The recommended starting dose of Sapropterin Amarox in patients with PKU &nbsp;is &nbsp;10 &nbsp;mg &nbsp;for &nbsp;each kg of body weight. &nbsp;Take Sapropterin Amarox as a single daily dose with &nbsp;a &nbsp;meal to &nbsp;increase &nbsp;the &nbsp;absorption, &nbsp;and at &nbsp;the &nbsp;same &nbsp;time &nbsp;each day, preferably in the morning. Your doctor may adjust &nbsp;your &nbsp;dose, &nbsp;usual y &nbsp;between 5 &nbsp;and &nbsp;20 &nbsp;mg &nbsp;for each kg of body weight per day, depending on your condition.<br />Dosing for BH4 deficiency<br />The recommended starting dose of Sapropterin Amarox in patients with BH4 deficiency is &nbsp;2 &nbsp;to &nbsp;5 &nbsp;mg &nbsp;for each kg of body weight. Take Sapropterin Amarox with a meal to increase the absorption. Divide the &nbsp;total daily dose into &nbsp;2 or 3 doses, taken over the day. Your doctor &nbsp;may &nbsp;adjust &nbsp;your &nbsp;dose up to 20 mg for each kg of body weight per day, depending on your condition.</p><p>The table below is an example of how an appropriate dose is calculated</p><p>Method of administration&nbsp;<br />For PKU patients, the total daily dose is taken once a day at the same time each day, preferably in the &nbsp;morning.&nbsp;<br />For BH4 deficiency patients, the total daily dose is divided into 2 or 3 doses over the &nbsp;day. &nbsp;<br />Use in al patients&nbsp;<br />Place the prescribed number of tablets in a glass or cup of water as accurately described below and stir until dissolved.&nbsp;<br />It may take a few minutes for the tablets to &nbsp;dissolve. &nbsp;To &nbsp;make &nbsp;the &nbsp;tablets &nbsp;dissolve &nbsp;faster &nbsp;you &nbsp;can crush them. Smal particles may be &nbsp;visible &nbsp;in &nbsp;the &nbsp;solution, &nbsp;but &nbsp;they &nbsp;wil &nbsp;not &nbsp;affect &nbsp;the &nbsp;effectiveness &nbsp;of &nbsp;the medicine Drink the dissolved preparation of &nbsp;Sapropterin Amarox &nbsp;with &nbsp;a &nbsp;meal &nbsp;within &nbsp;15 &nbsp;to &nbsp; 20 &nbsp;minutes &nbsp;of &nbsp;its &nbsp;preparation.&nbsp;<br />Do not swal ow the desiccant capsule contained in the bottle.&nbsp;<br />Use in patients above 20 kg body weight&nbsp;<br />Place the tablets in a glass or cup (120 to 240 ml) of water and stir until dissolved.&nbsp;<br />Use in children up to 20 kg body weight&nbsp;<br />The &nbsp;dose is &nbsp;based on body weight. &nbsp; This &nbsp;wil &nbsp; change &nbsp;as your &nbsp;child &nbsp; grows. &nbsp;Your &nbsp;doctor wil &nbsp; tel you:&nbsp;</p><p>&bull;&nbsp;&nbsp; &nbsp;the number &nbsp;of Sapropterin &nbsp;dihydrochloride &nbsp; Soluble &nbsp;tablets &nbsp;needed for &nbsp;one dose<br />&bull;&nbsp;&nbsp; &nbsp;the amount of water needed to mix one dose of Sapropterin dihydrochloride Soluble tablets<br />&bull;&nbsp;&nbsp; &nbsp;the amount of solution you wil need to give your child for their prescribed dose</p><p>Your child should &nbsp;drink &nbsp;the &nbsp;solution &nbsp;with &nbsp;a &nbsp;meal. &nbsp;Give &nbsp;your &nbsp;child &nbsp;the &nbsp;prescribed &nbsp;amount &nbsp;of &nbsp;solution &nbsp;within 15 to 20 minutes after dissolving. If you are not able &nbsp;to &nbsp;give &nbsp;your &nbsp;child&#39;s &nbsp;dose &nbsp;within &nbsp;15 &nbsp;to &nbsp;20 minutes after dissolving the tablets, &nbsp;you &nbsp;wil &nbsp;need &nbsp;to &nbsp;prepare &nbsp;a &nbsp;new &nbsp;solution &nbsp;as &nbsp;the &nbsp;unused &nbsp;solution &nbsp;should not be used beyond 20 minutes.&nbsp;<br />Supplies needed to prepare and give your child&#39;s dose of Sapropterin Amarox&nbsp;</p><p>&bull;&nbsp;&nbsp; &nbsp;The number of Sapropterin Amarox needed for one dose<br />&bull;&nbsp;&nbsp; &nbsp;A medicine cup with graduation markings at 20, 40, 60 and 80 ml<br />&bull;&nbsp;&nbsp; &nbsp;A glass or cup<br />&bull;&nbsp;&nbsp; &nbsp;Small spoon or clean utensil for stirring<br />&bull;&nbsp;&nbsp; &nbsp;Oral syringe (graduated in 1 ml divisions) &nbsp;(10 &nbsp;ml &nbsp;syringe &nbsp;for &nbsp;administration &nbsp;of volumes &nbsp;of &lt; 10 ml or 20 ml syringe for administration of volumes of &gt; 10 ml)</p><p>Ask your doctor for the medicine cup &nbsp;for &nbsp;dissolving &nbsp;the &nbsp;tablets &nbsp;and &nbsp;the &nbsp;10 &nbsp;ml &nbsp;or &nbsp;20 &nbsp;ml &nbsp;oral syringe &nbsp;if &nbsp;you do not have these supplies.&nbsp;<br />Steps for preparing and taking your dose:&nbsp;</p><p>Place the prescribed number of tablets in the medicine cup. Pour the amount of &nbsp;water &nbsp;into &nbsp;the medicine cup, as instructed by your doctor (e.g. &nbsp;your &nbsp;doctor &nbsp;told &nbsp;you to &nbsp;use &nbsp;20 ml for dissolving one Sapropterin Amarox). Check to make sure that the amount of liquid lines up with the amount that your doctor tel s you. Stir with the smal spoon or clean utensil until tablets dissolve.</p><p>&bull; &nbsp;&nbsp; &nbsp;If your doctor told you to administer only &nbsp;portion &nbsp;of &nbsp;the &nbsp;solution, &nbsp;point &nbsp;the &nbsp;tip &nbsp;of &nbsp;the &nbsp;oral syringe into &nbsp;the &nbsp;medicine &nbsp;cup. &nbsp;Slowly &nbsp;pul &nbsp;back &nbsp;the &nbsp;plunger &nbsp;to &nbsp; withdraw &nbsp;the &nbsp;amount &nbsp;as instructed by your doctor.<br />&bull; &nbsp;&nbsp; &nbsp;Transfer the solution by &nbsp;pushing &nbsp;on &nbsp;the &nbsp;plunger &nbsp;slowly &nbsp;until &nbsp;al &nbsp;of &nbsp;the &nbsp;solution &nbsp;in &nbsp;the &nbsp;oral syringe is transferred to a &nbsp;glass &nbsp;cup &nbsp;for &nbsp;administration &nbsp;(e.g. &nbsp;if &nbsp;your &nbsp;doctor &nbsp;told &nbsp;you &nbsp;to &nbsp;dissolve two Sapropterin Amarox in 40 ml water and administer 30 &nbsp;ml &nbsp;to your &nbsp;child, &nbsp;you would &nbsp;have &nbsp;to use the 20 ml oral syringe two times to draw up 30 ml (e.g. 20 ml + 10 ml) of the &nbsp;solution and transfer it to &nbsp;a &nbsp;glass or cup for &nbsp;administration). &nbsp;Use &nbsp;a &nbsp;10 &nbsp;ml &nbsp;oral syringe &nbsp;for &nbsp;administration &nbsp;of volumes &nbsp;&lt; 10 ml or a 20 ml oral syringe for administration of volumes &gt; 10 ml.<br />&bull; &nbsp;&nbsp; &nbsp;If your baby is too smal to drink &nbsp;from &nbsp;a &nbsp;glass &nbsp;or a cup &nbsp;you may administer &nbsp;the &nbsp;solution via the oral syringe. &nbsp;Draw &nbsp;up &nbsp;the &nbsp;prescribed &nbsp;volume &nbsp;from &nbsp;the &nbsp;solution &nbsp;prepared &nbsp;in &nbsp;the &nbsp;medicine &nbsp;cup and place the tip of the oral syringe into your &nbsp;baby&rsquo;s &nbsp;mouth. &nbsp;Point &nbsp;the &nbsp;tip &nbsp;of the &nbsp;oral syringe towards either cheek. Push on the plunger slowly, &nbsp;a &nbsp;smal &nbsp;amount &nbsp;at &nbsp;a &nbsp;time, &nbsp;until &nbsp;al &nbsp;of &nbsp;the solution in the oral syringe is given.</p><p>Throw away any remaining solution. Remove the plunger &nbsp;from &nbsp;the &nbsp;barrel &nbsp;of &nbsp;the &nbsp;oral &nbsp;syringe. Wash both parts of the oral syringe and &nbsp;the &nbsp;medicine &nbsp;cup &nbsp;with &nbsp;warm water &nbsp;and &nbsp;air &nbsp;dry. &nbsp;When the oral syringe is dry, put the plunger back &nbsp;into &nbsp;the &nbsp;barrel. &nbsp;Store &nbsp;the &nbsp;oral &nbsp;syringe &nbsp;and &nbsp;the medicine cup for next use.</p><p>If you take more Sapropterin Amarox than you should&nbsp;<br />If you take more tablets &nbsp;than &nbsp;prescribed, &nbsp;you &nbsp;may &nbsp;experience &nbsp;side &nbsp;effects &nbsp;that &nbsp;could &nbsp;include &nbsp;headache and dizziness. Immediately contact your doctor or pharmacist if you take more Sapropterin Amarox than prescribed.&nbsp;<br />If you forget to take Sapropterin Amarox&nbsp;<br />Do not take a double dose to make up for a forgotten dose. Take the next dose at the usual time.&nbsp;<br />If you stop taking Sapropterin Amarox&nbsp;<br />Do not stop &nbsp;taking &nbsp;Sapropterin Amarox &nbsp;without &nbsp;prior &nbsp;discussion &nbsp;with &nbsp;your &nbsp;doctor, &nbsp;as &nbsp;phenylalanine &nbsp;levels &nbsp;in &nbsp;your blood may increase.&nbsp;<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like al medicines, this medicine can cause side effects, although not everybody gets them.<br />Few cases of al ergic reactions (such as skin rash and serious reactions) &nbsp;have &nbsp;been &nbsp;reported. &nbsp;Their &nbsp;frequency is not known (frequency cannot be estimated from the available data).&nbsp;<br />If you have red, &nbsp;itchy, &nbsp;raised &nbsp;areas &nbsp;(hives), &nbsp;runny &nbsp;nose, &nbsp;fast &nbsp;or &nbsp;uneven &nbsp;pulse, &nbsp;swel ing &nbsp;of &nbsp;your &nbsp;tongue and throat, &nbsp;sneezing, &nbsp;wheezing, &nbsp;serious &nbsp;difficulty &nbsp;in &nbsp;breathing &nbsp;or &nbsp;dizziness, &nbsp;you &nbsp;may &nbsp;be &nbsp;having &nbsp;a &nbsp;serious &nbsp;al ergic reaction to the medicine. If you notice these signs, contact your doctor immediately.&nbsp;<br />Very common side effects (may affect up to 1 in 10 people)&nbsp;<br />Headache and runny nose.&nbsp;<br />Common side effects (may affect up to 1 in 10 people)&nbsp;<br />Sore throat, nasal congestion or stuffy nose, cough, diarrhoea, vomiting, stomach ache, too low levels of phenylalanine in blood tests, indigestion and feeling sick (nausea) (see section &nbsp;2: &nbsp;&ldquo;Warnings &nbsp;and &nbsp;precautions&rdquo;).&nbsp;</p><p>Not known side effects (frequency cannot be estimated from the available data)&nbsp;<br />Gastritis &nbsp;(inflammation &nbsp;of &nbsp;the &nbsp;lining &nbsp;of &nbsp; the &nbsp; stomach), &nbsp; oesophagitis &nbsp; (inflammation &nbsp; of &nbsp;the &nbsp; lining &nbsp; of &nbsp;the gul et).&nbsp;<br />Reporting of side effects&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.&nbsp;</p><p>To report any side effect(s):&nbsp;</p><p>Saudi Arabia:</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o&nbsp;&nbsp; &nbsp;SFDA Call Center: 19999<br />o&nbsp;&nbsp; &nbsp;E-mail: npc.drug@sfda.gov.sa<br />o&nbsp;&nbsp; &nbsp;Website: https://ade.sfda.gov.sa/</p><p>Other GCC States:</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the &nbsp;expiry date, which is &nbsp;stated on the &nbsp;carton, &nbsp;bottle &nbsp;and &nbsp;blister &nbsp;after EXP. &nbsp;The expiry date refers to the last day of that month.&nbsp;<br />This medicinal product does not require any special storage conditions.&nbsp;<br />Do not throw away any medicines &nbsp;via &nbsp;wastewater &nbsp;or &nbsp;household &nbsp;waste. &nbsp;Ask &nbsp;your &nbsp;pharmacist &nbsp;how &nbsp;to throw away medicines you no longer use. These measures wil help protect the environment.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Sapropterin<br />Amarox contains<br />The active substance is Sapropterin dichydrochloride.</p><p>Each &nbsp;tablet &nbsp;contains &nbsp;100 mg &nbsp;Sapropterin &nbsp;Dihydrochloride &nbsp;(Equivalent &nbsp;to &nbsp;76.80mg &nbsp;of Sapropterin) The other ingredients are: Mannitol (Pearlitol 160C), Ascorbic acid, Crospovidone (Kollidon CL), Riboflavin, Colloidal silicon dioxide (Aerosil 200), Sodium Stearyl &nbsp;Fumarate, &nbsp;Mannitol &nbsp;(Pearlitol &nbsp;SD&nbsp;200)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                looks like? Sapropterin 
Amarox 100 mg : 
Off white to light yel ow, mottled round, tablets debossed with "I 1" on one side and plain on other side. 
How supplied: 
Sapropterin Amarox is Supplied in 120’s Count HDPE container. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer&nbsp;<br />Saudi Amarox Industrial Company&nbsp;<br />Al Jamiah Street, Al Malaz District&nbsp;<br />Riyadh 12629, Saudi Arabia&nbsp;<br />Tel &amp; Fax: +966 11 226 8850&nbsp;<br />Manufacturer &nbsp;<br />M/s Annora Pharma Private Limited&ndash; India&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised in October 2023, Version 1 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;ﻋﻠﻰ ﺛﻼﺛﺔ ﻣواد ﻓﻌﺎﻟﺔ: ﺳﺎﺑروﺑﺗﯾرﯾن وھﻲ ﻧﺳﺧﺔ اﺻطﻧﺎﻋﯾﺔ ﻣن ﻣﺎدة طﺑﯾﻌﯾﺔ ﻓﻲ اﻟﺟﺳم ﺗﺳﻣﻰ&nbsp;<br />ﺗﺗراھﯾدروﺑﯾوﺑﺗرﯾن )BH4(. ﺣﯾث ﯾﺣﺗﺎج اﻟﺟﺳم إﻟﻰ BH4 وذﻟك ﻻﺳﺗﺧدام ﺣﻣض أﻣﯾﻧﻲ ﯾﺳﻣﻰ ﻓﯾﻧﯾل أﻻﻧﯾن ﻣن أﺟل ﺑﻧﺎء ﺣﻣض أﻣﯾﻧﻲ آﺧر ﯾﺳﻣﻰ اﻟﺗﯾروزﯾن. &nbsp;<br />ﯾﺳﺗﺧدم ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;ﻟﻌﻼج ﺣﺎﻻت ﻓرط ﻓﯾﻧﯾل أﻻﻧﯾن اﻟدم )HPA( أو ﺑﯾﻠﺔ اﻟﻔﯾﻧﯾل ﻛﯾﺗون )PKU( ﻓﻲ اﻟﻣرﺿﻰ ﻣن ﺟﻣﯾﻊ &nbsp;اﻷﻋﻣﺎر. ﺗﺣدث ﺣﺎﻻت HPA وPKU وذﻟك ﺑﺳﺑب اﻟﻣﺳﺗوﯾﺎت ﻋﺎﻟﯾﺔ ﺑﺷﻛل ﻏﯾر طﺑﯾﻌﻲ ﻣن اﻟﻔﯾﻧﯾل أﻻﻧﯾن ﻓﻲ اﻟدم واﻟﺗﻲ ﯾﻣﻛن أن ﺗﻛون &nbsp;ﺿﺎرة. ﯾﻘﻠل ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;ﻣن ھذه اﻟﻣﺳﺗوﯾﺎت ﻟدى ﺑﻌض اﻟﻣرﺿﻰ اﻟذﯾن ﯾﺳﺗﺟﯾﺑون ﻟـBH4 &nbsp;وﯾﻣﻛن أن ﯾﺳﺎﻋد ﻓﻲ زﯾﺎدة ﻛﻣﯾﺔ اﻟﻔﯾﻧﯾل أﻻﻧﯾن اﻟﺗﻲ ﯾﻣﻛن ﺗﺿﻣﯾﻧﮭﺎ ﻓﻲ اﻟﻧظﺎم اﻟﻐذاﺋﻲ.&nbsp;<br />ﯾﺳﺗﺧدم ھذا اﻟدواء أﯾﺿًﺎ ﻟﻌﻼج ﻣرض وراﺛﻲ ﯾﺳﻣﻰ ﻧﻘص ﺗﺗراھﯾدروﺑﯾوﺑﺗرﯾن BH4 ﻓﻲ اﻟﻣرﺿﻰ ﻣن ﺟﻣﯾﻊ اﻷﻋﻣﺎر، ﺣﯾث ﻻ ﯾﺳﺗطﯾﻊ اﻟﺟﺳم إﻧﺗﺎج ﻣﺎ ﯾﻛﻔﻲ ﻣن BH4 ﺑﺳﺑب ﻣﺳﺗوﯾﺎت BH4 اﻟﻣﻧﺧﻔﺿﺔ ﺟدًا، ﻻ ﯾﺗم اﺳﺗﺧدام ﻓﯾﻧﯾل أﻻﻧﯾن ﺑﺷﻛل ﺻﺣﯾﺢ وﺗرﺗﻔﻊ &nbsp;ﻣﺳﺗوﯾﺎﺗﮫ، ﻣﻣﺎ ﯾؤدي إﻟﻰ آﺛﺎر ﺿﺎرة. ﻋن طرﯾﻖ اﺳﺗﺑدال BH4 اﻟذي ﻻ ﯾﺳﺗطﯾﻊ اﻟﺟﺳم إﻧﺗﺎﺟﮫ، ﯾﻘﻠل ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;اﻟﻔﺎﺋض اﻟﺿﺎر ﻟﻠﻔﯾﻧﯾل أﻻﻧﯾن ﻓﻲ اﻟدم وﯾزﯾد ﻣن اﻷﯾض اﻟﻐذاﺋﻲ ﻟﻠﻔﯾﻧﯾل أﻻﻧﯾن.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;ﻻ ﺗﺳﺗﺧدم ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;أﻗراص&nbsp;</p><p>إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﺣﺳﺎﺳﯾﺔ ﺗﺟﺎه ﺳﺎﺑروﺑﺗﯾرﯾن ﺛﻧﺎﺋﻲ ھﯾدروﻛﻠورﯾد أو أي ﻣن اﻟﻣﻛوﻧﺎت اﻷﺧرى ﻟﮭذا اﻟدواء )اﻟﻣدرﺟﺔ ﻓﻲ اﻟﻘﺳم ٦(.</p><p>ﺣذﯾرات واﻻﺣﺗﯾﺎطﺎت&nbsp;<br />ﺗﺣدث إﻟﻰ طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ أو اﻟﻣﻣرﺿﺔ ﻗﺑل ﺗﻧﺎول ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;ﻓﻲ اﻟﺣﺎﻻت اﻟﺗﺎﻟﯾﺔ</p><p>ﻛﺎن ﻋﻣرك ٦٥ ﺳﻧﺔ أو أﻛﺛر &nbsp;<br />إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﻣﺷﺎﻛل ﻓﻲ اﻟﻛﻠﻰ أو اﻟﻛﺑد</p><p>إذا ﻛﻧت ﻣرﯾﺿﺎ. ﯾوﺻﻰ ﺑﺎﺳﺗﺷﺎرة طﺑﯾب أﺛﻧﺎء اﻟﻣرض ﺣﯾث ﻗد ﺗرﺗﻔﻊ ﻣﺳﺗوﯾﺎت اﻟﻔﯾﻧﯾل أﻻﻧﯾن ﻓﻲ اﻟدم &nbsp;إذا ﻛﺎن ﻟدﯾك اﺳﺗﻌداد ﻟﻠﺗﺷﻧﺟﺎت &nbsp;</p><p>ﻋﻧدﻣﺎ ﺗﻌﺎﻟﺞ ﺑﺎﺳﺗﺧدام ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp; ﺳﯾﺧﺗﺑر طﺑﯾﺑك دﻣك ﻟﻠﺗﺣﻘﻖ ﻣن ﻛﻣﯾﺔ اﻟﻔﯾﻧﯾل أﻻﻧﯾن واﻟﺗﯾروزﯾن اﻟﺗﻲ ﯾﺣﺗوي ﻋﻠﯾﮭﺎ وﻗد ﯾﻘرر ﺗﻌدﯾل ﺟرﻋﺔ ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;أو ﻧظﺎﻣك اﻟﻐذاﺋﻲ إذا ﻟزم اﻷﻣر.&nbsp;</p><p>ﯾﺟب أن ﺗﺳﺗﻣر ﻓﻲ ﻧظﺎﻣك اﻟﻐذاﺋﻲ اﻟﻌﻼﺟﻲ ﻋﻠﻰ اﻟﻧﺣو اﻟذي أوﺻﻰ ﺑﮫ طﺑﯾﺑك. ﻻ ﺗﻐﯾر ﻧظﺎﻣك اﻟﻐذاﺋﻲ دون اﻻﺗﺻﺎل ﺑطﺑﯾﺑك. ﺣﺗﻰ إذا &nbsp;ﻛﻧت ﺗﺗﻧﺎول ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;إذا ﻟم ﯾﺗم اﻟﺗﺣﻛم ﻓﻲ ﻣﺳﺗوﯾﺎت اﻟﻔﯾﻧﯾل أﻻﻧﯾن ﻓﻲ اﻟدم ﺑﺷﻛل ﺟﯾد، ﻓﻘد ﯾﺣدث ﺗطوﯾر ﻣﺷﺎﻛل ﻋﺻﺑﯾﺔ ﺷدﯾدة. ﯾﺟب أن ﯾﺳﺗﻣر طﺑﯾﺑك ﻓﻲ ﻣراﻗﺑﺔ ﻣﺳﺗوﯾﺎت ﻓﯾﻧﯾل أﻻﻧﯾن ﻓﻲ اﻟدم ﻟدﯾك ﻛﺛﯾرً ا أﺛﻧﺎء اﻟﻌﻼج ﺑﺎﺳﺗﺧدام ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;ﻟﻠﺗﺄﻛد &nbsp;ﻣن أن ﻣﺳﺗوﯾﺎت ﻓﯾﻧﯾل أﻻﻧﯾن ﻓﻲ اﻟدم ﻟﯾﺳت ﻣرﺗﻔﻌﺔ ﺟدًا أو ﻣﻧﺧﻔﺿﺔ ﺟدًا.&nbsp;</p><p>ﻷدوﯾﺔ اﻷﺧرى و ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;أﻗراص</p><p>أﺧﺑر طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ إذا ﻛﻧت ﺗﺗﻧﺎول أو ﺗﻧﺎوﻟت ﻣؤﺧرًا أو ﻗد ﺗﺗﻧﺎول أي أدوﯾﺔ أﺧرى. ﻋﻠﻰ وﺟﮫ اﻟﺧﺻوص، ﯾﺟب أن ﺗﺧﺑر طﺑﯾﺑك إذا ﻛﻧت ﺗﺳﺗﺧدم</p><p>دوﺑﺎ )ﯾﺳﺗﺧدم ﻟﻌﻼج ﻣرض ﺑﺎرﻛﻧﺳون(&nbsp;<br />أدوﯾﺔ ﻟﻌﻼج اﻟﺳرطﺎن )ﻣﺛل اﻟﻣﯾﺛوﺗرﯾﻛﺳﺎت(.&nbsp;<br />اﻷدوﯾﺔ اﻟﻣﺳﺗﺧدﻣﺔ ﻟﻌﻼج اﻻﻟﺗﮭﺎﺑﺎت اﻟﺑﻛﺗﯾرﯾﺔ )ﻣﺛل ﺗراي ﻣﯾﺛوﺑرﯾم(.&nbsp;<br />اﻷدوﯾﺔ اﻟﺗﻲ ﺗﺳﺑب ﺗﻣدد اﻷوﻋﯾﺔ اﻟدﻣوﯾﺔ )ﻣﺛل&nbsp;&nbsp;)ﻣﺛل ﺟﻠﯾﺳﯾرﯾل ﺛﻼﺛﻲ اﻟﻧﺗرات )GTN(، ﺛﻧﺎﺋﻲ ﻧﺗرات إﯾزوﺳورﺑﯾد )ISDN(،ﻧﺗروﺑروﺳﯾد اﻟﺻودﯾوم )SNP(، &nbsp;ﻣوﻟﺳﯾدوﻣﯾن، &nbsp;ﻣﯾﻧوﻛﺳﯾدﯾل(</p><p>اﻟﺣﻣل واﻟرﺿﺎﻋﺔ</p><p>إذا ﻛﻧت ﺣﺎﻣﻼ أً و ﻣرﺿﻌﺔ، ﺗﻌﺗﻘدﯾن أﻧك ﺣﺎﻣل أو ﺗﺧططﯾن ﻹﻧﺟﺎب طﻔل، اﺳﺄﻟﻲ طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ ﻟﻠﺣﺻول ﻋﻠﻰ اﻟﻣﺷورة ﻗﺑل ﺗﻧﺎول ھذا اﻟدواء.&nbsp;<br />إذا ﻛﻧت ﺣﺎﻣﻼً، ﺳﯾﺧﺑرك طﺑﯾﺑك ﺑﻛﯾﻔﯾﺔ اﻟﺗﺣﻛم ﻓﻲ ﻣﺳﺗوﯾﺎت اﻟﻔﯾﻧﯾل أﻻﻧﯾن ﺑﺷﻛل ﻣﻧﺎﺳب. إذا ﻟم ﯾﺗم اﻟﺗﺣﻛم ﻓﯾﮭﺎ ﺑﺷﻛل ﺻﺎرم ﻗﺑل أو ﻋﻧدﻣﺎ ﺗﺻﺑﺣﯾن ﺣﺎﻣﻼً، ﻓﻘد ﯾﻛون ذﻟك ﺿﺎرًا ﻟك وﻟطﻔﻠك. ﺳﯾراﻗب طﺑﯾﺑك ﻗﯾود ﺗﻧﺎول ﻓﯾﻧﯾل أﻻﻧﯾن اﻟﻐذاﺋﻲ ﻗﺑل وأﺛﻧﺎء اﻟﺣﻣل<br />إذا ﻛﺎن اﻟﻧظﺎم اﻟﻐذاﺋﻲ اﻟﺻﺎرم ﻻ ﯾﻘﻠل ﺑﺷﻛل ﻛﺎفٍ ﻣن ﻛﻣﯾﺔ اﻟﻔﯾﻧﯾل أﻻﻧﯾن ﻓﻲ دﻣك، ﻓﺳوف ﯾﻔﻛر طﺑﯾﺑك ﻓﯾﻣﺎ إذا ﻛﺎن ﯾﺟب ﻋﻠﯾك ﺗﻧﺎول ھذا اﻟدواء.&nbsp;</p><p>ﺟب ﻋدم ﺗﻧﺎول ھذا اﻟدواء إذا ﻛﻧت ﻣرﺿﻌﺔ.&nbsp;</p><p>ﯾﺎدة واﺳﺗﺧدام اﻵﻻت&nbsp;<br />ﻻ ﯾﺗوﻗﻊ أن ﺗﻧﺎول ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;ﯾؤﺛر ﻋﻠﻰ اﻟﻘدرة ﻋﻠﻰ اﻟﻘﯾﺎدة واﺳﺗﺧدام اﻵﻻت.</p><p>ﺗوي ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;ﻋﻠﻰ اﻟﺻودﯾوم&nbsp;<br />ﯾﺣﺗوي ھذا اﻟدواء ﻋﻠﻰ أﻗل ﻣن ۱ ﻣﻠﯾﻣول ﺻودﯾوم ۲۳ ﻣﻠﻐم( ﻟﻛل ﻗرص، وھذا ﯾﻌﻧﻲ ﺑﺷﻛل أﺳﺎﺳﻲ ﺧﺎلٍ ﻣن اﻟﺻودﯾوم&quot;.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>اﺣرص داﺋﻣًﺎ ﻋﻠﻰ ﺗﻧﺎول ھذا اﻟدواء ﺗﻣﺎﻣًﺎ ﻛﻣﺎ أﺧﺑرك طﺑﯾﺑك. اﺳﺗﺷر طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ إذا ﻟم ﺗﻛن ﻣﺗﺄﻛدًا.</p><p>ﺟرﻋﺎت ﺑﯾﻠﺔ اﻟﻔﯾﻧﯾل ﻛﯾﺗون&nbsp;</p><p>ﺟرﻋﺔ اﻟﺑدء اﻟﻣوﺻﻰ ﺑﮭﺎ ﻣن ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;ﻓﻲ ﻣرﺿﻰ ﺑﯾﻠﺔ اﻟﻔﯾﻧﯾل ﻛﯾﺗون ھﻲ ۱۰ ﻣﻠﺟراﻣﻠﻛل ﻛﯾﻠوﻏرام ﻣن وزن اﻟﺟﺳم. ﯾﺗم ﺗﻧﺎول ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;أﻗراص ﻛﺟرﻋﺔ ﯾوﻣﯾﺔ واﺣدة ﻣﻊ اﻟوﺟﺑﺔ ﻟزﯾﺎدة اﻻﻣﺗﺻﺎص، وﻓﻲ ﻧﻔس اﻟوﻗت ﻛل ﯾوم وﯾﻔﺿل ﻓﻲ اﻟﺻﺑﺎح. ﻗد ﯾﻘوم طﺑﯾﺑك ﺑﺗﻌدﯾل ﺟرﻋﺗك، ﻋﺎدةً ﻣﺎ ﺑﯾن ٥ و۲۰ &nbsp;ﻣﻠﺟراﻣﻠﻛل ﻛﯾﻠوﻏرام ﻣن وزن اﻟﺟﺳم ﯾوﻣﯾﺎ،ً ﺣﺳب ﺣﺎﻟﺗك.&nbsp;</p><p>ﺟرﻋﺎت ﻧﻘص ﺗﺗراھﯾدروﺑﯾوﺑﺗرﯾن &nbsp;</p><p>رﻋﺔ اﻟﺑدء اﻟﻣوﺻﻰ ﺑﮭﺎ ﻣن ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;ﻓﻲ اﻟﻣرﺿﻰ اﻟذﯾن ﯾﻌﺎﻧون ﻣن ﻧﻘص BH4 ھﻲ &nbsp;۲ إﻟﻰ ٥ ﻣﻠﺟراﻣﻠﻛل ﻛﯾﻠوﻏرام ﻣن &nbsp;وزن اﻟﺟﺳم. ﯾﺗم ﺗﻧﺎول ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;ﻣﻊ اﻟوﺟﺑﺔ ﻟزﯾﺎدة اﻻﻣﺗﺻﺎص. وﯾﺗم ﺗﻘﺳﯾم اﻟﺟرﻋﺔ اﻟﯾوﻣﯾﺔ اﻹﺟﻣﺎﻟﯾﺔ إﻟﻰ ﺟرﻋﺗﯾن أو ﺛﻼث &nbsp;ﺟرﻋﺎت ﺗؤﺧذ ﻋﻠﻰ ﻣدار اﻟﯾوم. ﻗد ﯾﻘوم طﺑﯾﺑك ﺑﺗﻌدﯾل ﺟرﻋﺗك ﺣﺗﻰ ۲۰ ﻣﻠﺟراﻣﻠﻛل ﻛﯾﻠوﻏرام ﻣن وزن اﻟﺟﺳم ﯾوﻣﯾﺎ،ً ﺣﺳب ﺣﺎﻟﺗك.&nbsp;</p><p>اﻟﺟدول أدﻧﺎه ھو ﻣﺛﺎل ﻋﻠﻰ ﻛﯾﻔﯾﺔ ﺣﺳﺎب اﻟﺟرﻋﺔ اﻟﻣﻧﺎﺳﺑﺔ&nbsp;</p><p>طرﯾﻘﺔ اﻻﺳﺗﺧدام</p><p>ﺑﺎﻟﻧﺳﺑﺔ ﻟﻣرﺿﻰ ﺑﯾﻠﺔ اﻟﻔﯾﻧﯾل ﻛﯾﺗون PKU، ﺗؤﺧذ اﻟﺟرﻋﺔ اﻟﯾوﻣﯾﺔ اﻹﺟﻣﺎﻟﯾﺔ ﻣرة واﺣدة ﯾوﻣﯾﺎ ً ﻓﻲ ﻧﻔس اﻟوﻗت ﻛل ﯾوم، وﯾﻔﺿل أن ﯾﻛون ذﻟك &nbsp;ﻓﻲ اﻟﺻﺑﺎح.&nbsp;</p><p>ﺑﺎﻟﻧﺳﺑﺔ ﻟﻣرﺿﻰ ﻧﻘص BH4، ﯾﺗم ﺗﻘﺳﯾم اﻟﺟرﻋﺔ اﻟﯾوﻣﯾﺔ اﻹﺟﻣﺎﻟﯾﺔ إﻟﻰ ﺟرﻋﺗﯾن أو ﺛﻼث ﺟرﻋﺎت ﻋﻠﻰ ﻣدار اﻟﯾوم. اﺳﺗﺧدم ﻓﻲ ﺟﻣﯾﻊ اﻟﻣرﺿﻰ &nbsp;</p><p>ﺿﻊ اﻟﻌدد اﻟﻣوﺻوف ﻣن اﻷﻗراص ﻓﻲ ﻛوب أو ﻛوب ﻣﺎء ﻛﻣﺎ ھو ﻣوﺻوف ﺑدﻗﺔ أدﻧﺎه وﺣرﻛﮫ ﺣﺗﻰ ﯾذوب.</p><p>&nbsp;ﯾﺳﺗﻐرق اﻷﻣر ﺑﺿﻊ دﻗﺎﺋﻖ ﺣﺗﻰ ﺗذوب اﻷﻗراص. ﻟﺟﻌل اﻷﻗراص ﺗذوب ﺑﺷﻛل أﺳرع، &nbsp;ﯾﻣﻛﻧك ﺳﺣﻘﮭﺎ. ﻗد ﺗظﮭر اﻟﺟزﯾﺋﺎت اﻟﺻﻐﯾرة ﻓﻲ اﻟﻣﺣﻠول، ﻟﻛﻧﮭﺎ ﻟن ﺗؤﺛر ﻋﻠﻰ ﻓﻌﺎﻟﯾﺔ اﻟدواء. اﺷرب اﻟﻣﺳﺗﺣﺿر اﻟﻣذاب ﻣن ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;ﻣﻊ اﻟوﺟﺑﺔ ﺧﻼل ۱٥ إﻟﻰ ۲۰ دﻗﯾﻘﺔ ﻣن ﺗﺣﺿﯾرھﺎ.&nbsp;</p><p>ﻻ ﺗﺑﺗﻠﻊ ﻛﺑﺳوﻟﺔ ﻣﺎدة اﻟﺗﺟﻔﯾف اﻟﻣوﺟودة ﻓﻲ اﻟزﺟﺎﺟﺔ ﻛﻣﺎدة ﺣﺎﻓظﺔ ﻣن اﻟرطوﺑﺔ. &nbsp;اﻻﺳﺗﺧدام ﻓﻲ ﺣﺎﻻت اﻟﻣرﺿﻰ اﻟذﯾن ﯾزﯾد وزﻧﮭم ﻋن ۲۰ ﻛﻐم&nbsp;<br />ﺿﻊ اﻷﻗراص ﻓﻲ ﻛوب أو ﻛوب )۱۲۰ إﻟﻰ ۲٤۰ ﻣل( ﻣن اﻟﻣﺎء وﺣرﻛﮫ ﺣﺗﻰ ﯾذوب اﻻﺳﺗﺧدام ﻓﻲ ﺣﺎﻻت اﻷطﻔﺎل ﺣﺗﻰ وزن ۲۰ ﻛﺟم&nbsp;<br />ﺗﻌﺗﻣد اﻟﺟرﻋﺔ ﻋﻠﻰ وزن اﻟﺟﺳم. ﺳوف ﯾﺗﻐﯾر ھذا ﻣﻊ ﻧﻣو طﻔﻠك. ﺳﯾﺧﺑرك طﺑﯾﺑك: &nbsp;</p><p>د أﻗراص ﺳﺎﺑروﺑﺗﯾرﯾن ﺛﻧﺎﺋﻲ ھﯾدروﻛﻠورﯾد اﻟﻘﺎﺑﻠﺔ ﻟﻠذوﺑﺎن اﻟﻼزﻣﺔ ﻟﺟرﻋﺔ واﺣدة &nbsp;<br />ﻛﻣﯾﺔ اﻟﻣﺎء اﻟﻼزﻣﺔ ﻟﺧﻠط ﺟرﻋﺔ واﺣدة ﻣن أﻗراص ﺳﺎﺑروﺑﺗﯾرﯾن ﺛﻧﺎﺋﻲ ھﯾدروﻛﻠورﯾد اﻟﻘﺎﺑﻠﺔ ﻟﻠذوﺑﺎن ﻛﻣﯾﺔ اﻟﻣﺣﻠول اﻟﺗﻲ ﺳﺗﺣﺗﺎﺟﮭﺎ ﻹﻋطﺎء طﻔﻠك اﻟﺟرﻋﺔ اﻟﻣوﺻوﻓﺔ&nbsp;</p><p>&nbsp;ﯾﺟب أن ﯾﺷرب طﻔﻠك اﻟﻣﺣﻠول ﻣﻊ اﻟوﺟﺑﺔ. اﻣﻧﺢ طﻔﻠك اﻟﻛﻣﯾﺔ اﻟﻣوﺻوﻓﺔ ﻣن اﻟﻣﺣﻠول ﻓﻲ ﻏﺿون ۱٥ إﻟﻰ ۲۰ دﻗﯾﻘﺔ ﺑﻌد اﻟذوﺑﺎن. إذا ﻟم ﺗﻛن ﻗﺎدرً ا ﻋﻠﻰ إﻋطﺎء ﺟرﻋﺔ طﻔﻠك ﻓﻲ ﻏﺿون ۱٥ إﻟﻰ ۲۰ دﻗﯾﻘﺔ ﺑﻌد إذاﺑﺔ اﻷﻗراص، ﻓﺳﺗﺣﺗﺎج إﻟﻰ ﺗﺣﺿﯾر ﻣﺣﻠول ﺟدﯾد ﺣﯾث ﻻ ﯾﻧﺑﻐﻲ</p><p>ﺗﺧدام اﻟﻣﺣﻠول ﻏﯾر اﻟﻣﺳﺗﺧدم ﻷﻛﺛر ﻣن ۲۰ دﻗﯾﻘﺔ.&nbsp;<br />اﻷدوات اﻟﻼزﻣﺔ ﻟﺗﺣﺿﯾر وإﻋطﺎء طﻔﻠك ﺟرﻋﺔ ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس</p><p>دد أﻗراص ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;اﻟﻼزم ﻟﺟرﻋﺔ واﺣدة&nbsp;<br />ﻛوب دواء ﺑﻌﻼﻣﺎت ﺗدرﯾﺞ ۲۰ و٤۰ و٦۰ &nbsp;و۸۰ &nbsp;ﻣل&nbsp;<br />ﻛوب &nbsp;<br />ﻣﻠﻌﻘﺔ ﺻﻐﯾرة أو إﻧﺎء ﻧظﯾف ﻟﻠﺗﻘﻠﯾب &nbsp;<br />ﻣﺣﻘﻧﺔ ﻋن طرﯾﻖ اﻟﻔم )ﻣﺗدرﺟﺔ ﺑﺣﯾث ﯾﻛون ﻛل ﻗﺳم &nbsp;۱ ﻣل( )۱۰ ﻣل ﺣﻘﻧﺔ ﻹﻋطﺎء أﺣﺟﺎم أﻗل ﻣن ۱۰ ﻣل أو ۲۰ ﻣل ﺣﻘﻧﺔ &nbsp;ﻹﻋطﺎء أﺣﺟﺎم أﻛﺑر ﻣن &nbsp;۱۰ ﻣل( &nbsp;</p><p>اﺳﺄل طﺑﯾﺑك ﻋن ﻛوب اﻟدواء ﻹذاﺑﺔ اﻷﻗراص واﻟﻣﺣﻘﻧﺔ ﻋن طرﯾﻖ اﻟﻔم ۱۰ ﻣل أو ۲۰ ﻣل إذا ﻟم ﯾﻛن ﻟدﯾك ھذه اﻷدوات. ﺧطوات ﺗﺣﺿﯾر اﻟﺟرﻋﺔ وﺗﻧﺎوﻟﮭﺎ&nbsp;</p><p>ﺿﻊ اﻟﻌدد اﻟﻣوﺻوف ﻣن اﻷﻗراص ﻓﻲ ﻛوب اﻟدواء. ﺻب ﻛﻣﯾﺔ اﻟﻣﺎء ﻓﻲ ﻛوب اﻟدواء، ﺣﺳب ﺗﻌﻠﯾﻣﺎت طﺑﯾﺑك ﻋﻠﻰ ﺳﺑﯾل &nbsp;اﻟﻣﺛﺎل، أﺧﺑرك طﺑﯾﺑك ﺑﺎﺳﺗﺧدام ۲۰ ﻣل ﻹذاﺑﺔ ﻗرص واﺣد ﻣن ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;ﺗﺣﻘﻖ ﻟﻠﺗﺄﻛد ﻣن أن ﻛﻣﯾﺔ اﻟﺳﺎﺋل ﺗﺗواﻓﻖ ﻣﻊ اﻟﻛﻣﯾﺔ اﻟﺗﻲ ﯾﺧﺑرك ﺑﮭﺎ طﺑﯾﺑك. ﻗم ﺑﺎﻟﺗﻘﻠﯾب ﺑﻣﻠﻌﻘﺔ ﺻﻐﯾرة أو إﻧﺎء ﻧظﯾف ﺣﺗﻰ ﺗذوب اﻷﻗراص.&nbsp;<br />إذا أﺧﺑرك طﺑﯾﺑك ﺑﺎﺳﺗﺧدام ﺟزء ﻓﻘط ﻣن اﻟﻣﺣﻠول، ﻓﻘم ﺑﺗوﺟﯾﮫ طرف اﻟﻣﺣﻘﻧﺔ اﻟﻔﻣوﯾﺔ ﻓﻲ ﻛوب اﻟدواء. اﺳﺣب اﻟﻣﻛﺑس ﺑﺑطء ﻟﺳﺣب اﻟﻛﻣﯾﺔ ﺣﺳب ﺗﻌﻠﯾﻣﺎت اﻟطﺑﯾب.&nbsp;<br />اﻧﻘل اﻟﻣﺣﻠول ﻋن طرﯾﻖ اﻟﺿﻐط ﻋﻠﻰ اﻟﻣﻛﺑس ﺑﺑطء ﺣﺗﻰ ﯾﺗم ﻧﻘل ﻛل اﻟﻣﺣﻠول اﻟﻣوﺟود ﻓﻲ اﻟﻣﺣﻘﻧﺔ اﻟﻔﻣوﯾﺔ إﻟﻰ ﻛوب زﺟﺎﺟﻲ ﻟﻺﻋطﺎء )ﻋﻠﻰ ﺳﺑﯾل اﻟﻣﺛﺎل، إذا أﺧﺑرك طﺑﯾﺑك ﺑﺣل ﻗرﺻﯾن ﻣن &nbsp;ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp; ﻓﻲ ٤۰ ﻣل ﻣن اﻟﻣﺎء وإﻋطﺎء ۳۰ ﻣل ﻟطﻔﻠك، ﯾﺟب ﻋﻠﯾك اﺳﺗﺧدام ﺣﻘﻧﺔ ۲۰ ﻣل ﻋن طرﯾﻖ اﻟﻔم ﻣرﺗﯾن ﻟﺳﺣب ۳۰ ﻣل &nbsp;۱۰ ﻣل( ﻣن &nbsp;اﻟﻣﺣﻠول وﻧﻘﻠﮫ إﻟﻰ ﻛوب أو ﻛوب ﻟﻺﻋطﺎء(. اﺳﺗﺧدم ﺣﻘﻧﺔ ﻓﻣوﯾﺔ ﺑﺣﺟم ۱۰ ﻣل ﻹﻋطﺎء أﺣﺟﺎم أﻗل ﻣن ۱۰ ﻣل أو ۲۰ ﻣل ﺣﻘﻧﺔ ﻓﻣوﯾﺔ ﻹﻋطﺎء اﻷﺣﺟﺎم&lt; ۱۰ ﻣل. &nbsp;<br />إذا ﻛﺎن طﻔﻠك أﺻﻐر ﻣن أن ﯾﺷرب ﻣن اﻟﻛوب، ﯾﻣﻛﻧك إﻋطﺎء اﻟﻣﺣﻠول ﻋن طرﯾﻖ اﻟﻣﺣﻘﻧﺔ اﻟﻔﻣوﯾﺔ. اﺳﺣب اﻟﺣﺟم اﻟﻣوﺻوف &nbsp;ﻣن اﻟﻣﺣﻠول اﻟﻣﻌد ﻓﻲ ﻛوب اﻟدواء وﺿﻊ طرف اﻟﻣﺣﻘﻧﺔ اﻟﻔﻣوﯾﺔ ﻓﻲ ﻓم طﻔﻠك. وﺟﮭﻲ طرف اﻟﻣﺣﻘﻧﺔ اﻟﻔﻣوﯾﺔ ﺑﺎﺗﺟﺎه أي ﻣن اﻟﺧدﯾن. اﺿﻐط ﻋﻠﻰ اﻟﻣﻛﺑس ﺑﺑطء ﻹﺧراج ﻛﻣﯾﺔ ﺻﻐﯾرة ﻓﻲ ﻛل ﻣرة، &nbsp;ﺣﺗﻰ ﯾﺗم إﻋطﺎء ﻛل اﻟﻣﺣﻠول ﻓﻲ اﻟﻣﺣﻘﻧﺔ اﻟﻔﻣوﯾﺔ. ﺗﺧﻠص ﻣن أي ﻣﺣﻠول ﻣﺗﺑﻘﻲ. ﻗم ﺑﺈزاﻟﺔ اﻟﻣﻛﺑس ﻣن ﻓوھﺔ ﺣﻘﻧﺔ اﻟﻔم. اﻏﺳل ﻛﻼ اﻟﺟزأﯾن ﻣن اﻟﻣﺣﻘﻧﺔ اﻟﻔﻣوﯾﺔ وﻛوب اﻟدواء ﺑﺎﻟﻣﺎء اﻟداﻓﺊ وﺟﻔﻔﮭﺎ ﺑﺎﻟﮭواء. ﻋﻧدﻣﺎ ﺗﺟف اﻟﻣﺣﻘﻧﺔ اﻟﻔﻣوﯾﺔ، أﻋد اﻟﻣﻛﺑس إﻟﻰ ﻣوﺿﻌﮫ. ﻗم ﺑﺗﺧزﯾن اﻟﻣﺣﻘﻧﺔ اﻟﻔﻣوﯾﺔ وﻛوب اﻟدواء ﻟﻼﺳﺗﺧدام اﻟﺗﺎﻟﻲ</p><p>ل ﺟرﻋﺔ زاﺋدة ﻣن ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;أﻗراص&nbsp;</p><p>إذا ﺗﻧﺎوﻟت أﻗراﺻًﺎ أﻛﺛر ﻣن اﻟﻣوﺻوﻓﺔ، ﻓﻘد ﺗواﺟﮫ آﺛﺎرًا ﺟﺎﻧﺑﯾﺔ ﻗد ﺗﺷﻣل اﻟﺻداع واﻟدوﺧﺔ. اﺗﺻل ﻋﻠﻰ اﻟﻔور ﺑطﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ إذا &nbsp;ﺗﻧﺎوﻟت ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;أﻛﺛر ﻣﻣﺎ ھو ﻣوﺻوف. &nbsp;</p><p>ت أن ﺗﺗﻧﺎول ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;أﻗراص &nbsp;<br />ﻻ ﺗﺗﻧﺎول ﺟرﻋﺔ ﻣﺿﺎﻋﻔﺔ ﻟﺗﻌوﯾض اﻟﺟرﻋﺔ اﻟﻣﻧﺳﯾﺔ. ﺗﻧﺎول اﻟﺟرﻋﺔ اﻟﺗﺎﻟﯾﺔ ﻓﻲ اﻟوﻗت اﻟﻣﻌﺗﺎد.</p><p>وﻗف ﻋن ﺗﻧﺎول ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;أﻗراص&nbsp;<br />ﻻ ﺗﺗوﻗف ﻋن ﺗﻧﺎول ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;دون ﻣﻧﺎﻗﺷﺔ ﻣﺳﺑﻘﺔ ﻣﻊ طﺑﯾﺑك، ﺣﯾث ﻗد ﺗرﺗﻔﻊ ﻣﺳﺗوﯾﺎت اﻟﻔﯾﻧﯾل أﻻﻧﯾن ﻓﻲ دﻣك</p><p>إذا ﻛﺎن ﻟدﯾك أي أﺳﺋﻠﺔ أﺧرى ﺣول اﺳﺗﺧدام ھذا اﻟدواء، اﺳﺄل طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>ﻣﺛل ﺟﻣﯾﻊ اﻷدوﯾﺔ، ﯾﻣﻛن أن ﯾﺳﺑب ھذا اﻟدواء آﺛﺎرً ا ﺟﺎﻧﺑﯾﺔ، ﻋﻠﻰ اﻟرﻏم ﻣن ﻋدم ﺣدوﺛﮭﺎ ﻟدى اﻟﺟﻣﯾﻊ.&nbsp;</p><p>ﺗم اﻹﺑﻼغ ﻋن ﺣﺎﻻت ﻗﻠﯾﻠﺔ ﻣن ردود اﻟﻔﻌل اﻟﺗﺣﺳﺳﯾﺔ )ﻣﺛل اﻟطﻔﺢ اﻟﺟﻠدي وردود اﻟﻔﻌل اﻟﺧطﯾرة(. ﻣﻌدﻻﺗﮭﺎ ﻏﯾر ﻣﻌروف )ﻻ ﯾﻣﻛن ﺗﻘدﯾر ﻣﻌدﻻﺗﮭﺎ ﻣن اﻟﺑﯾﺎﻧﺎت اﻟﻣﺗﺎﺣﺔ(.&nbsp;<br />إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﻣﻧﺎطﻖ ﺣﻣراء أو ﺣﻛﺔ أو اﻟﺷرى، &nbsp;أو ﺳﯾﻼن اﻷﻧف، &nbsp;أو ﻧﺑض ﺳرﯾﻊ أو ﻏﯾر ﻣﻧﺗظم، أو ﺗورم ﻟﺳﺎﻧك وﺣﻠﻘك، أو ﻋطس، &nbsp;أو أزﯾز، أو ﺻﻌوﺑﺔ ﺧطﯾرة ﻓﻲ اﻟﺗﻧﻔس أو دوار، ﻓﻘد ﯾﻛون ﻟدﯾك رد ﻓﻌل ﺗﺣﺳﺳﻲ ﺧطﯾر ﻟﻠدواء. إذا ﻻﺣظت ھذه اﻟﻌﻼﻣﺎت، &nbsp;ﻓﺎﺗﺻل ﺑطﺑﯾﺑك &nbsp;ﻋﻠﻰ اﻟﻔور. &nbsp;</p><p>ﻋراض ﺟﺎﻧﺑﯾﺔ ﺷﺎﺋﻌﺔ ﺟدًا )ﻗد ﺗظﮭر ﻟدى ﺣﺗﻰ ﺷﺧص ﻣن ﻛل ۱۰ أﺷﺧﺎص( &nbsp;ﺻداع وﺳﯾﻼن اﻷﻧف.&nbsp;<br />أﻋراض ﺟﺎﻧﺑﯾﺔ ﺷﺎﺋﻌﺔ )ﻗد ﺗظﮭر ﻟدى ﺣﺗﻰ ﺷﺧص &nbsp;ﻣن ﻛل ۱۰ أﺷﺧﺎص( &nbsp;</p><p>ب اﻟﺣﻠﻖ، اﺣﺗﻘﺎن اﻷﻧف أو اﻧﺳداد اﻷﻧف، ﺳﻌﺎل، &nbsp;إﺳﮭﺎل، ﻗﻲء، آﻻم ﻓﻲ اﻟﻣﻌدة، ﻣﺳﺗوﯾﺎت ﻣﻧﺧﻔﺿﺔ ﺟدًا ﻣن ﻓﯾﻧﯾل أﻻﻧﯾن ﻓﻲ اﺧﺗﺑﺎرات اﻟدم، ﻋﺳر ھﺿم وﺷﻌور ﺑﺎﻟﻐﺛﯾﺎن اﻟﺗﺣذﯾرات واﻻﺣﺗﯾﺎطﺎت&quot;(. &nbsp;</p><p>&nbsp;أﻋراض ﺟﺎﻧﺑﯾﺔ ﻏﯾر ﻣﻌروﻓﺔ ﻣﻌدﻻﺗﮭﺎ )ﻻ ﯾﻣﻛن ﺗﻘدﯾر ﻣﻌدﻻﺗﮭﺎ ﻣن اﻟﺑﯾﺎﻧﺎت اﻟﻣﺗﺎﺣﺔ</p><p>اﻟﺗﮭﺎب اﻟﻣﻌدة )اﻟﺗﮭﺎب ﺑطﺎﻧﺔ اﻟﻣﻌدة(، اﻟﺗﮭﺎب اﻟﻣريء )اﻟﺗﮭﺎب ﺑطﺎﻧﺔ اﻟﻣريء(.</p><p>ﻹﺑﻼغ ﻋن اﻷﻋراض اﻟﺟﺎﻧﺑﯾﺔ اﻟﻣﺷﺗﺑﮫ ﺑﮭﺎ<br />إن ﻛﺎن ﻟدﯾك أﻋراض ﺟﺎﻧﺑﯾﺔ أو ﻻﺣظت أﻋراض ﺟﺎﻧﺑﯾﺔ ﻏﯾر ﻣذﻛورة ﻓﻲ ھذه اﻟﻧﺷرة، ﻓﺿﻼً &nbsp;اﺑﻠﻎ اﻟطﺑﯾب أواﻟﺻﯾدﻟﻲ</p><p>ﻟﻺﺑﻼغ ﺣول اﻷﻋراض اﻟﺟﺎﻧﺑﯾﺔ اﻟﺗﻲ ﻗد ﺗﺣدث ﯾرﺟﻰ اﻟﺗواﺻل ﻋﺑر اﻟﻌﻧﺎوﯾن اﻟﺗﺎﻟﯾﺔ:</p><p>&nbsp;ﻟﻺﺑﻼغ ﻋن اﻷﻋراض اﻟﺟﺎﻧﺑﯾﺔ</p><p>اﻟﻣﻣﻠﻛﺔ اﻟﻌرﺑﯾﺔ اﻟﺳﻌودﯾﺔ&nbsp;<br />&nbsp;اﻟﻣرﻛز اﻟوطﻧﻲ ﻟﻠﺗﯾﻘظ واﻟﺳﻼﻣﺔ اﻟدواﺋﯾﺔ &nbsp;o ﻣرﻛز اﻻﺗﺻﺎل ﺑﺎﻟﮭﯾﺋﺔ اﻟﻌﺎﻣﺔ ﻟﻠﻐذاء واﻟدواء: 19999</p><p>npc.drug@sfda.gov.sa :اﻟﺑرﯾد اﻹﻟﻛﺗروﻧﻲ o https://ade.sfda.gov.saاﻟﻣوﻗﻊ اﻹﻟﻛﺗروﻧﻲ: &nbsp;</p><p>ول ﻣﺟﻠس اﻟﺗﻌﺎون اﻟﺧﻠﯾﺟﻲ اﻷﺧرى: &nbsp;ﯾرﺟﻰ اﻻﺗﺻﺎل ﺑﺎﻟﺳﻠطﺔ اﻟﺻﺣﯾﺔ اﻟﻣﺧﺗﺻﺔ</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ﻔظ ھذا اﻟدواء ﺑﻌﯾدًا ﻋن رؤﯾﺔ وﻣﺗﻧﺎول أﯾدي اﻷطﻔﺎل.&nbsp;<br />ﻻ ﺗﺳﺗﺧدم ھذا اﻟدواء ﺑﻌد ﺗﺎرﯾﺦ اﻧﺗﮭﺎء اﻟﺻﻼﺣﯾﺔ اﻟﻣذﻛور ﻋﻠﻰ اﻟﻌﺑوة ﺑﻌد EXP. ﯾﺷﯾر ﺗﺎرﯾﺦ اﻧﺗﮭﺎء اﻟﺻﻼﺣﯾﺔ إﻟﻰ اﻟﯾوم &nbsp;اﻷﺧﯾر ﻣن اﻟﺷﮭر.&nbsp;<br />ﻻ ﯾﺗطﻠب ھذا اﻟﻣﻧﺗﺞ اﻟطﺑﻲ أي ﺷروط ﺗﺧزﯾن ﺧﺎﺻﺔ.&nbsp;<br />ﻻ ﺗﺗﺧﻠص ﻣن اﻷدوﯾﺔ ﻓﻲ ﻣﯾﺎه اﻟﺻرف اﻟﺻﺣﻲ أو اﻟﻧﻔﺎﯾﺎت اﻟﻣﻧزﻟﯾﺔ. اﺳﺄل اﻟﺻﯾدﻟﻲ ﻋن ﻛﯾﻔﯾﺔ اﻟﺗﺧﻠص ﻣن اﻷدوﯾﺔ اﻟﺗﻲ ﻟم ﺗﻌد ﺑﺣﺎﺟﺔ إﻟﯾﮭﺎ. ﺳﺗﺳﺎﻋد ھذه اﻹﺟراءات ﻓﻲ ﺣﻣﺎﯾﺔ اﻟﺑﯾﺋﺔ.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ذا ﺗﺣﺗوي ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;أﻗراص ﻋﻠﻰ:&nbsp;<br />اﻟﻣﺎدة اﻟﻔﻌﺎﻟﺔ ھﻲ ﺳﺎﺑروﺑﺗﯾرﯾن ﺛﻧﺎﺋﻲ ھﯾدروﻛﻠورﯾد&nbsp;<br />ﯾﺣﺗوي ﻛل ﻗرص ﯾﺣﺗوي ﻛل ﻗرص ﻋﻠﻰ ۱۰۰ ﻣﻠﺟراﻣﺳﺎﺑروﺑﺗﯾرﯾن ﺛﻧﺎﺋﻲ ھﯾدروﻛﻠورﯾد )ﻣﺎ ﯾﻌﺎدل ۷٦٫۸۰ ﻣﻠﺟراﻣﻣن ﺳﺎﺑروﺑﺗﯾرﯾن(.&nbsp;</p><p>اﻟﺻواﻏﺎت اﻷﺧرى ھﻲ: ﻣﺎﻧﯾﺗول )ﺑﯾرﻟﯾﺗول ۱٦۰ ﺳﻲ(، ﺣﻣض اﻷﺳﻛورﺑﯾك، ﻛروﺳﺑوﻓﯾدون )ﻛوﻟﯾدون ﺳﻲ إل(، رﯾﺑوﻓﻼﻓﯾن، ﺛﺎﻧﻲ أﻛﺳﯾد اﻟﺳﯾﻠﯾﻛون اﻟﻐرواﻧﻲ )إﯾروﺳﯾل ۲۰۰(، ﺳﺗﯾرﯾل ﻓوﻣﺎرﯾت اﻟﺻودﯾوم. ﻣﺎﻧﯾﺗول )ﺑﯾرﻟﯾﺗول SD 200(&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ﺎ ھو ﺷﻛل ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;أﻗراص؟ &nbsp;ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;أﻗراص ۱۰۰ ﻣﻠﻐم</p><p>ﻗراص ﻣﺳﺗدﯾرة ﻣﻐﻠﻔﺔ ﺑطﺑﻘﺔ رﻗﯾﻘﺔ ذات اﻟﻠون اﻷﺑﯾض اﻟﻔﺎﺗﺢ إﻟﻰ اﻷﺻﻔر اﻟﻔﺎﺗﺢ ﻣدﻣوغ ﻋﻠﯾﮭﺎ &quot;I 1 &quot; ﻋﻠﻰ ﺟﺎﻧب واﺣد وﻣﻠﺳﺎء ﻣن اﻟﺟﺎﻧب اﻵﺧر.&nbsp;</p><p>ﯾﺔ ﺗوﻓﯾر ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;أﻗراص؟ &nbsp;<br />ﯾﺣﺗوي ﺳﺎﺑروﺑﺗﯾرﯾن اﻣﺎروﻛس &nbsp;۱۰۰ ﻣﻠﺟرام أﻗراص ﻓﻲ ﻋﺑوة ﺑﮭﺎ ۱۲۰ ﻗرص&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>اﺳم وﻋﻧوان ﻣﺎﻟك رﺧﺻﺔ اﻟﺗﺳوﯾﻖ واﻟﻣﺻﻧﻊ ﺻﺎﺣب ﺣﻖ اﻟﺗﺳوﯾﻖ:&nbsp;<br />ﺷرﻛﺔ اﻣﺎروﻛس اﻟﺳﻌودﯾﺔ اﻟﺻﻧﺎﻋﯾﺔ ﺷﺎرع اﻟﺟﺎﻣﻌﺔ ، ﺣﻲ اﻟﻣﻠز &nbsp;&nbsp;<br />اﻟرﯾﺎض ۱۲٦۲۹ ، اﻟﻣﻣﻠﻛﺔ اﻟﻌرﺑﯾﺔ اﻟﺳﻌودﯾﺔ&nbsp;</p><p>+966 11 226 8850 &nbsp; ھﺎﺗف و ﻓﺎﻛس:</p><p>ﺻﻧﻊ &nbsp;<br />ﺷرﻛﺔ أﻧورا ﻓﺎرﻣﺎ اﻟﻣﺣدودة، اﻟﮭﻧ</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             ﻣراﺟﻌﺔ ھذه  اﻟﻧﺷرة ﻓﻲ اﻛﺗوﺑر ۲۰۲۳, ﻧﺳﺧﺔ  ۱ 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sapropterin Amarox (Sapropterin dihydrochloride 100 mg Tablets)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sapropterin Amarox (Sapropterin dihydrochloride 100 mg Tablets):
Each soluble tablet contains 100 mg of sapropterin dihydrochloride (equivalent to  77 mg of sapropterin).
For the ful list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sapropterin Amarox (Sapropterin dihydrochloride 100 mg Tablets):
Off white to light yel ow, mottled round, tablets  debossed  with  "I  1"  on  one  side  and  plain  on other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sapropterin dihydrochloride is&nbsp; indicated&nbsp; for&nbsp; the&nbsp; treatment&nbsp; of&nbsp; hyperphenylalaninaemia&nbsp; (HPA)&nbsp; in adults and paediatric&nbsp; patients&nbsp; of&nbsp; a<strong>l&nbsp; </strong>ages&nbsp; with&nbsp; phenylketonuria&nbsp; (PKU)&nbsp; who&nbsp; have&nbsp; been&nbsp; shown&nbsp; to be responsive to such treatment (see section 4.2).</p><p>Sapropterin&nbsp; dihydrochloride&nbsp; is&nbsp; also indicated&nbsp;&nbsp; for&nbsp; the&nbsp; treatment&nbsp; of&nbsp; hyperphenylalaninaemia&nbsp; (HPA) in adults and paediatric patients of&nbsp; a<strong>l&nbsp; </strong>ages&nbsp; with&nbsp; tetrahydrobiopterin&nbsp; (BH4)&nbsp; deficiency&nbsp; who&nbsp; have been shown to be responsive to such treatment (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Sapropterin&nbsp; dihydrochloride must be initiated and supervised by a&nbsp; physician experienced in the treatment of PKU and BH4 deficiency.</p><p>Active&nbsp; management&nbsp; of&nbsp; dietary&nbsp; phenylalanine&nbsp; and&nbsp; overa<strong>l&nbsp; </strong>protein&nbsp;&nbsp; intake&nbsp;&nbsp; while&nbsp;&nbsp; taking&nbsp;&nbsp; this medicinal product is required to ensure adequate control of blood phenylalanine levels and nutritional balance.</p><p>&nbsp;</p><p>&nbsp;</p><p>As HPA due to either PKU or BH4 deficiency is a chronic condition, once responsiveness is demonstrated, Sapropterin dihydrochloride is intended for long-term use (see section 5.1).</p><p><u>Posology</u></p><p>&nbsp;</p><p><em>PKU</em></p><p><em>&nbsp;</em></p><p>The starting dose of Sapropterin dihydrochloride in adult and paediatric patients&nbsp; with&nbsp; PKU is&nbsp; 10 mg/kg body weight once daily. The dose is adjusted, usua<strong>l </strong>y between&nbsp; 5&nbsp; and&nbsp; 20&nbsp; mg/kg/day,&nbsp; to achieve and maintain adequate blood phenylalanine levels as defined by the physician.</p><p><em>BH4 deficiency</em></p><p><em>&nbsp;</em></p><p>The starting dose of Sapropterin&nbsp; dihydrochloride in&nbsp; adult&nbsp; and&nbsp; paediatric&nbsp; patients&nbsp; with&nbsp; BH4 deficiency is&nbsp; 2 to&nbsp; 5 mg/kg body weight&nbsp; total daily&nbsp; dose. Doses&nbsp; may be adjusted&nbsp; up&nbsp; to&nbsp; a total of&nbsp;&nbsp; 20 mg/kg per day.</p><p>Sapropterin dihydrochloride is provided as 100 mg&nbsp; tablets.&nbsp; The&nbsp; calculated&nbsp; daily&nbsp; dose&nbsp; based&nbsp; on body weight should be rounded to the nearest&nbsp; multiple&nbsp; of 100.&nbsp; For&nbsp; instance,&nbsp; a calculated dose of 401 to 450 mg should&nbsp; be rounded&nbsp; down to&nbsp; 400 mg corresponding to&nbsp; 4 tablets.&nbsp; A calculated&nbsp; dose&nbsp; of 451 mg to 499 mg should be rounded up to 500 mg corresponding to 5 tablets.</p><p><em><u>Dose adjustment</u></em></p><p><em>&nbsp;</em></p><p>Treatment&nbsp; with&nbsp; sapropterin&nbsp; may&nbsp; decrease&nbsp; blood&nbsp; phenylalanine&nbsp; levels&nbsp; below&nbsp;&nbsp; the&nbsp;&nbsp; desired therapeutic level. Adjustment of the Sapropterin dihydrochloride dose or modification of dietary phenylalanine intake&nbsp; may&nbsp; be&nbsp; required to&nbsp; achieve&nbsp; and&nbsp; maintain&nbsp; blood&nbsp; phenylalanine levels within&nbsp;&nbsp; the desired therapeutic range.</p><p>Blood phenylalanine and&nbsp; tyrosine&nbsp; levels&nbsp; should&nbsp; be&nbsp; tested, &nbsp;particularly &nbsp;in &nbsp;the&nbsp;&nbsp; paediatric population, one to two weeks after&nbsp; each&nbsp; dose&nbsp; adjustment&nbsp; and&nbsp; monitored&nbsp; frequently&nbsp; thereafter,&nbsp; under the direction of the treating physician.</p><p>If inadequate control of blood phenylalanine levels is observed during treatment with Sapropterin dihydrochloride, the patient&#39;s adherence to the prescribed treatment, and diet, should&nbsp; be&nbsp; reviewed before considering an adjustment of the dose of sapropterin.</p><p>&nbsp;</p><p>&nbsp;</p><p>Discontinuation of treatment should be done only under the supervision of a physician. More frequent monitoring may be required, as&nbsp; blood&nbsp; phenylalanine&nbsp; levels&nbsp; may&nbsp; increase.&nbsp; Dietary modification may be&nbsp; necessary &nbsp;to &nbsp;maintain blood phenylalanine levels within the&nbsp; desired therapeutic range.</p><p><em><u>Determination of response</u></em></p><p><em>&nbsp;</em></p><p>It is of primary importance to initiate treatment as early as possible to avoid the appearance of non-reversible clinical&nbsp; manifestations&nbsp; of&nbsp; neurological&nbsp; disorders&nbsp;&nbsp; in&nbsp;&nbsp; paediatric&nbsp;&nbsp; patients&nbsp;&nbsp; and&nbsp; cognitive deficits and psychiatric disorders in adults due to&nbsp; sustained&nbsp; elevations&nbsp; of&nbsp; blood phenylalanine.</p><p>Response to this medicinal product is determined by a decrease in blood phenylalanine. Blood phenylalanine levels should&nbsp; be&nbsp; checked &nbsp;before&nbsp; administering&nbsp; Sapropterin &nbsp;dihydrochloride&nbsp; and&nbsp; after 1 week of use at the recommended starting dose. If an unsatisfactory reduction in blood phenylalanine levels is observed, then the dose can be increased weekly to a maximum of&nbsp; 20 mg/kg/day, with continued weekly monitoring of&nbsp; blood&nbsp; phenylalanine&nbsp; levels&nbsp; over&nbsp; a&nbsp; one&nbsp; month period. The dietary phenylalanine intake&nbsp; should&nbsp; be&nbsp; maintained&nbsp; at&nbsp; a&nbsp; constant&nbsp; level&nbsp; during&nbsp; this&nbsp; period.</p><p>A satisfactory response is defined as a &ge;30 percent reduction in blood phenylalanine levels or attainment of the therapeutic blood phenylalanine goals defined&nbsp; for&nbsp; an&nbsp; individual&nbsp; patient&nbsp; by&nbsp; the treating physician. Patients who fail&nbsp; to&nbsp; achieve&nbsp; this&nbsp; level&nbsp; of&nbsp; response&nbsp; within&nbsp; the&nbsp; described&nbsp; one month test period should be considered non-responsive, these patients should not be treated with Sapropterin dihydrochloride and administration of Sapropterin dihydrochloride should be discontinued.</p><p>Once responsiveness to the medicinal product has been established,&nbsp; the&nbsp; dose&nbsp; may&nbsp; be&nbsp; adjusted&nbsp; within the range of 5 to 20 mg/kg/day according to response to therapy.</p><p>It is recommended that blood phenylalanine and tyrosine levels&nbsp; be&nbsp; tested&nbsp; one&nbsp; or two&nbsp; weeks&nbsp; after each dose adjustment and monitored frequently thereafter under&nbsp; the&nbsp; direction&nbsp; of&nbsp; the&nbsp; treating physician.</p><p>&nbsp;</p><p>&nbsp;</p><p>Patients treated &nbsp;with&nbsp; Sapropterin&nbsp; dihydrochloride&nbsp; must&nbsp; continue&nbsp; a&nbsp; restricted&nbsp;&nbsp; phenylalanine&nbsp;&nbsp; diet and undergo regular clinical assessment (such as monitoring&nbsp; of&nbsp; blood&nbsp; phenylalanine&nbsp; and&nbsp; tyrosine levels, nutrient intake, and psycho-motor development).</p><p><em><u>Special population</u></em></p><p><em>&nbsp;</em></p><p><em>Elderly</em></p><p><em>&nbsp;</em></p><p>Safety and efficacy of Sapropterin dihydrochloride in&nbsp; patients&nbsp; above&nbsp; 65&nbsp; years&nbsp; of&nbsp; age&nbsp; have&nbsp; not&nbsp; been established. Caution must be exercised when prescribing to elderly patients.</p><p><em>Renal or hepatic impairment</em></p><p><em>&nbsp;</em></p><p>Safety and efficacy of Sapropterin dihydrochloride&nbsp; in&nbsp; patients&nbsp; with&nbsp; renal&nbsp; or&nbsp; hepatic&nbsp; insufficiency have not been established. Caution must be exercised when prescribing to such patients.</p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>The posology is the same in adults, children, and adolescents. <u>Method of administration</u></p><p>Sapropterin&nbsp; &nbsp;dihydrochloride&nbsp;&nbsp;&nbsp; tablets&nbsp;&nbsp;&nbsp;&nbsp; should&nbsp;&nbsp;&nbsp; be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; administered&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with&nbsp; &nbsp;a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; meal to&nbsp; increase the absorption.</p><p>For patients with PKU, Sapropterin dihydrochloride should be administered as a single daily dose, and at the same time each day preferably in the morning.</p><p>For patients with BH4 deficiency, divide the total &nbsp;daily dose into 2 or 3 administrations, distributed over the day.</p><p>Patients should be advised not to swa<strong>l </strong>ow the desiccant capsule found in the bottle.</p><p>&nbsp;</p><p>The prescribed number of tablets should be placed in a glass or cup of water and&nbsp; stirred&nbsp; until&nbsp; dissolved. It may take a few minutes for the tablets to dissolve. To make the tablets dissolve faster they can be crushed. Sma<strong>l </strong>particles may be visible in the solution and wi<strong>l </strong>not affect the effectiveness of the medicinal product. The solution should be drank within 15 to 20 minutes.</p><p><em>Patients above 20 kg body weight</em></p><p>&nbsp;</p><p><em>&nbsp;</em></p><p>The prescribed number of tablets should be placed&nbsp; in a glass&nbsp; or cup&nbsp; with 120 to&nbsp; 240 ml of water &nbsp;and stirred until dissolved.</p><p><em>Children up to 20 kg body weight</em></p><p><em>&nbsp;</em></p><p>The measuring devices required for dosing in children up to 20 kg body weight (i.e. cup with graduations at 20, 40, 60,&nbsp; 80&nbsp; ml;&nbsp; 10 ml and&nbsp; 20 ml oral syringes&nbsp; with graduation at 1 ml divisions)&nbsp; are not included in the Sapropterin dihydrochloride pack.</p><p>Depending on the dose (in mg/kg/day) the appropriate number of tablets should be dissolved in a volume of water&nbsp; as depicted in&nbsp; Tables 1-4,&nbsp; whereby&nbsp; the&nbsp; volume&nbsp; of&nbsp; the&nbsp; solution&nbsp; to&nbsp;&nbsp; be administered is calculated according to the prescribed total daily dose. The prescribed&nbsp; number&nbsp; of tablets for a 2, 5, 10 and 20 mg/kg/day dose&nbsp; should&nbsp; be&nbsp; placed&nbsp; in&nbsp; a&nbsp; cup&nbsp; (that&nbsp; shows&nbsp; the&nbsp; appropriate graduation markings at 20, 40, 60 and 80 ml) with the amount of water as depicted in Tables 1-4 and stirred until dissolved.</p><p>If only a portion of this solution needs to be administered, an oral&nbsp; syringe&nbsp; should&nbsp; be&nbsp; used&nbsp; to&nbsp; withdraw the volume of solution to&nbsp; be&nbsp; administered.&nbsp; The&nbsp; solution&nbsp; may&nbsp; then&nbsp; be&nbsp; transferred&nbsp; to another cup for administration of the medicinal product. For&nbsp; sma<strong>l</strong><strong> </strong>infants an oral syringe can&nbsp; be used. A 10 ml oral syringe should be used for&nbsp; administration&nbsp; of volumes&nbsp; of &le;10&nbsp; ml&nbsp; and&nbsp; a&nbsp; 20&nbsp; ml oral syringe for administration of volumes of &gt;10 ml.</p><p>Table 1: 2 mg/kg per day dosing table for children weighing up to 20 kg</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>Total dose (mg/day)</strong></p></td><td style="vertical-align:top"><p><strong>Number of tablets to be dissolved (100 mg strength only)</strong></p></td><td style="vertical-align:top"><p><strong>Volume </strong><strong>of dissolution (ml)</strong></p></td><td style="vertical-align:top"><p><strong>Volume of solution to be administered (ml)*</strong></p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>8</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>13</p></td></tr><tr><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>16</p></td></tr><tr><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>18</p></td></tr><tr><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>19</p></td></tr><tr><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>21</p></td></tr><tr><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>22</p></td></tr><tr><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>24</p></td></tr><tr><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>26</p></td></tr><tr><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>27</p></td></tr><tr><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>29</p></td></tr><tr><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>30</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>32</p></td></tr></tbody></table><p>*Reflects volume for total daily dose.</p><p>&nbsp;</p><p>Discard unused solution within 20 minutes for tablet solution.</p><p>&nbsp;</p><p>Table 2: 5 mg/kg per day dosing table for children weighing up to 20 kg</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>Total dose (mg/day)</strong></p></td><td style="vertical-align:top"><p><strong>Number of tablets to be dissolved (100 mg strength only)</strong></p></td><td style="vertical-align:top"><p><strong>Volume </strong><strong>of dissolution (ml)</strong></p></td><td style="vertical-align:top"><p><strong>Volume of solution to be administered (ml)*</strong></p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>8</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>16</p></td></tr><tr><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>18</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>20</p></td></tr><tr><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>55</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>22</p></td></tr><tr><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>24</p></td></tr><tr><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>65</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>26</p></td></tr><tr><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>70</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>28</p></td></tr><tr><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>30</p></td></tr><tr><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>32</p></td></tr><tr><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>85</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>34</p></td></tr><tr><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>90</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>36</p></td></tr><tr><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>95</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>38</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>40</p></td></tr></tbody></table><p>*Reflects volume for total daily dose.</p><p>&nbsp;</p><p>Discard unused solution within 20 minutes for tablet solution.</p><p>&nbsp;</p><p>Table 3: 10 mg/kg per day dosing table for children weighing up to 20 kg</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>Total dose (mg/day)</strong></p></td><td style="vertical-align:top"><p><strong>Number of tablets to be dissolved (100 mg strength only)</strong></p></td><td style="vertical-align:top"><p><strong>Volume </strong><strong>of dissolution (ml)</strong></p></td><td style="vertical-align:top"><p><strong>Volume of solution to be administered (ml)*</strong></p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>6</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>70</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>16</p></td></tr><tr><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>90</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>18</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>20</p></td></tr><tr><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>110</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>22</p></td></tr><tr><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>120</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>24</p></td></tr><tr><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>130</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>26</p></td></tr><tr><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>140</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>28</p></td></tr><tr><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>30</p></td></tr><tr><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>160</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>32</p></td></tr><tr><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>170</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>34</p></td></tr><tr><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>180</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>36</p></td></tr><tr><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>190</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>38</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>200</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>40</p></td></tr></tbody></table><p>*Reflects volume for total daily dose.</p><p>&nbsp;</p><p>Discard unused solution within 20 minutes for tablet solution.</p><p>&nbsp;</p><p>Table 4: 20 mg/kg per day dosing table for children weighing up to 20 kg</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>Total dose (mg/day)</strong></p></td><td style="vertical-align:top"><p><strong>Number of tablets to be dissolved (100 mg strength only)</strong></p></td><td style="vertical-align:top"><p><strong>Volume </strong><strong>of dissolution (ml)</strong></p></td><td style="vertical-align:top"><p><strong>Volume of solution to be administered (ml)*</strong></p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>8</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>16</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>20</p></td></tr><tr><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>120</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>24</p></td></tr><tr><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>140</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>28</p></td></tr><tr><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>160</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>32</p></td></tr><tr><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>180</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>36</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>200</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>40</p></td></tr><tr><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>220</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>44</p></td></tr><tr><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>240</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>48</p></td></tr><tr><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>260</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>52</p></td></tr><tr><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>280</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>56</p></td></tr><tr><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>60</p></td></tr><tr><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>320</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>64</p></td></tr><tr><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>340</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>68</p></td></tr><tr><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>360</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>72</p></td></tr><tr><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>380</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>76</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>400</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>80</p></td></tr></tbody></table><p>*Reflects volume for total daily dose.</p><p>&nbsp;</p><p>Discard unused solution within 20 minutes for tablet solution.</p><p>&nbsp;</p><p>For cleaning, the plunger should be removed&nbsp; from&nbsp; the barrel of the&nbsp; oral syringe.&nbsp; Both parts of the oral syringe and the cup should be washed with warm&nbsp; water and air&nbsp; dry. When&nbsp; the oral syringe&nbsp; is dry, the plunger should&nbsp; be put back into&nbsp; the&nbsp; barrel.&nbsp; The&nbsp; oral syringe&nbsp; and the&nbsp; cup should&nbsp; be stored for next use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Dietary intake</u></p><p>&nbsp;</p><p>Patients treated &nbsp;with&nbsp; Sapropterin&nbsp; dihydrochloride&nbsp; must&nbsp; continue&nbsp; a&nbsp; restricted&nbsp;&nbsp; phenylalanine&nbsp;&nbsp; diet and undergo regular clinical assessment (such as monitoring&nbsp; of&nbsp; blood&nbsp; phenylalanine&nbsp; and&nbsp; tyrosine levels, nutrient intake, and psycho-motor development).</p><p><u>Low blood phenylalanine and tyrosine levels</u></p><p>&nbsp;</p><p>Sustained&nbsp; or&nbsp; recurrent&nbsp; dysfunction&nbsp; in&nbsp;&nbsp; the&nbsp;&nbsp; phenylalanine-tyrosine-dihydroxy-L-phenylalanine (DOPA) metabolic pathway can result in deficient body protein and neurotransmitter synthesis. Prolonged exposure to low blood phenylalanine and tyrosine&nbsp; levels&nbsp; during&nbsp; infancy&nbsp; has&nbsp; been associated&nbsp; with&nbsp; impaired&nbsp; neurodevelopmental outcome.&nbsp; Active&nbsp; management&nbsp; of&nbsp; dietary phenylalanine and overa<strong>l</strong><strong> </strong>protein intake while&nbsp; taking&nbsp; Sapropterin&nbsp; dihydrochloride&nbsp; is&nbsp; required to ensure adequate control of blood phenylalanine and tyrosine levels and nutritional balance.</p><p><u>Health disturbances</u></p><p>&nbsp;</p><p>Consultation with a physician is recommended during i<strong>l </strong>ness as blood phenylalanine levels may increase<em>.</em></p><p><u>Convulsions disorders</u></p><p>&nbsp;</p><p>Caution should be exercised when prescribing sapropterin dihydrochloride to patients receiving treatment with levodopa. Cases of convulsion, exacerbation&nbsp; of&nbsp; convulsion,&nbsp; increased&nbsp; excitability and irritability have been observed during co-administration of levodopa and sapropterin in BH4- deficient patients (see section 4.5).</p><p><u>Discontinuation of treatment</u></p><p>&nbsp;</p><p>Rebound,&nbsp; as&nbsp; defined&nbsp; by&nbsp; an&nbsp; increase&nbsp; in&nbsp; blood&nbsp; phenylalanine levels above&nbsp; pre-treatment&nbsp; levels, may occur upon cessation of treatment.</p><p><u>Sodium content</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg)&nbsp; per&nbsp; tablet,&nbsp; that&nbsp; is&nbsp; to&nbsp; say&nbsp; essentially &#39;sodium-free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Although concomitant administration of inhibitors of dihydrofolate reductase (e.g. methotrexate, trimethoprim)&nbsp; has&nbsp; not&nbsp; been&nbsp; studied,&nbsp; such&nbsp; medicinal&nbsp; products&nbsp; may&nbsp;&nbsp; interfere&nbsp;&nbsp; with&nbsp;&nbsp; BH4 metabolism. Caution is&nbsp; recommended when using such&nbsp; medicinal&nbsp; products while taking Sapropterin dihydrochloride.</p><p>BH4 is a cofactor for nitric oxide synthetase. Caution is recommended during concomitant use of Sapropterin dihydrochloride with a<strong>l </strong>medicinal products that cause vasodilation, including those administered&nbsp; topica<strong>l </strong>y,&nbsp; by&nbsp; affecting&nbsp; nitric&nbsp; oxide&nbsp; (NO)&nbsp; metabolism&nbsp; or&nbsp; action&nbsp;&nbsp; including&nbsp;&nbsp; classical NO donors (e.g. glyceryl trinitrate (GTN), isosorbide dinitrate&nbsp; (ISDN),&nbsp; sodium&nbsp; nitroprusside (SNP), molsidomin), phosphodiesterase type 5 (PDE-5) inhibitors and minoxidil.</p><p>Caution should be exercised when prescribing sapropterin dihydrochloride to patients receiving treatment with levodopa. Cases of convulsion, exacerbation&nbsp; of&nbsp; convulsion,&nbsp; increased&nbsp; excitability and irritability have been observed during co-administration of levodopa and sapropterin in BH4- deficient patients</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are&nbsp; limited&nbsp; amount&nbsp; of&nbsp; data&nbsp; from&nbsp; the&nbsp; use&nbsp; of&nbsp; sapropterin&nbsp; dihydrochloride&nbsp; in&nbsp; pregnant women. Animal studies do&nbsp; not&nbsp; indicate&nbsp; direct&nbsp; or&nbsp; indirect&nbsp; harmful&nbsp; effects&nbsp; with&nbsp; respect&nbsp; to&nbsp; pregnancy, embryonal/foetal development, parturition or postnatal development.</p><p>Available disease-associated maternal and/or embryofoetal risk data from the Maternal Phenylketonuria Co<strong>l </strong>aborative Study on&nbsp; a&nbsp; moderate&nbsp; amount&nbsp; of&nbsp; pregnancies&nbsp; and&nbsp; live&nbsp; births (between 300-1,000) in PKU-affected &nbsp;women demonstrated that&nbsp; uncontro<strong>l </strong>ed&nbsp; phenylalanine levels above 600 &mu;mol/l are associated with a very high incidence of neurological, cardiac, facial dysmorphism, and growth anomalies.</p><p>Maternal blood phenylalanine levels must therefore be strictly contro<strong>l </strong>ed before and during pregnancy.&nbsp; If&nbsp; maternal&nbsp; phenylalanine&nbsp; levels&nbsp; are&nbsp; not&nbsp; strictly&nbsp; contro<strong>l </strong>ed&nbsp; before&nbsp; and&nbsp; during pregnancy, this could be harmful to the mother and the foetus. Physician-supervised restriction</p><p>&nbsp;</p><p>&nbsp;</p><p>of dietary&nbsp; phenylalanine intake prior to and throughout pregnancy is the first choice of&nbsp; treatment in this patient group.</p><p>The use of Sapropterin dihydrochloride should be considered only&nbsp; if&nbsp; strict&nbsp; dietary&nbsp; management does not adequately reduce&nbsp; blood phenylalanine levels. Caution&nbsp; must&nbsp; be&nbsp; exercised&nbsp; when&nbsp; prescribing to pregnant women.</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is not known whether sapropterin or its&nbsp; metabolites&nbsp; are&nbsp; excreted&nbsp; in&nbsp; human&nbsp; breast&nbsp; milk. Sapropterin dihydrochloride should not be used during breast-feeding.</p><p><u>Fertility</u></p><p>&nbsp;</p><p>In preclinical studies, no effects of sapropterin on male and female fertility were observed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sapropterin dihydrochloride has no&nbsp; or&nbsp; negligible&nbsp; influence&nbsp; on&nbsp; the&nbsp; ability&nbsp; to&nbsp;&nbsp; drive&nbsp; and&nbsp; use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary&nbsp;&nbsp; of the&nbsp; safety profile</u></p><p>&nbsp;</p><p>Approximately 35% of the 579 patients aged 4 years and over who received treatment&nbsp; with&nbsp; sapropterin&nbsp; dihydrochloride&nbsp; (5&nbsp; to&nbsp; 20&nbsp; mg/kg/day)&nbsp; in&nbsp; the&nbsp; clinical&nbsp; trials&nbsp; for&nbsp; sapropterin dihydrochloride&nbsp; experienced adverse &nbsp;reactions.&nbsp; The&nbsp; most&nbsp; commonly&nbsp; reported&nbsp; adverse&nbsp; reactions are headache and rhinorrhoea.</p><p>In a further clinical trial, approximately 30% of the 27 children aged below 4 years who received treatment with sapropterin dihydrochloride (10 or 20 mg/kg/day) experienced adverse reactions. The most commonly reported adverse reactions are &ldquo;amino acid level decreased&rdquo; (hypophenylalaninaemia), vomiting and rhinitis.</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>In the pivotal clinical trials&nbsp; and&nbsp; in&nbsp; the&nbsp; post-marketing&nbsp; experience&nbsp; for&nbsp; sapropterin&nbsp; dihydrochloride,&nbsp; the fo<strong>l </strong>owing adverse reactions have been identified.</p><p>&nbsp;</p><p>&nbsp;</p><p>The fo<strong>l </strong>owing definitions apply to the frequency terminology used hereafter:</p><p>&nbsp;</p><p>very common (&ge;1/10), common (&ge;1/100 to&nbsp; &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be&nbsp; estimated&nbsp; from available data)</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><em><u>Immune system disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions (including serious a<strong>l </strong>ergic reactions) and rash</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>Metabolism and nutrition disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Hypophenylalaninaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>Nervous system disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>Respiratory, thoracic and mediastinal disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Rhinorrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Pharyngolaryngeal pain, nasal congestion, cough</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em><u>Gastrointestinal disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Diarrhoea, vomiting, abdominal pain, dyspepsia, nausea</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Gastritis, oesophagitis</p></td></tr></tbody></table><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Frequency, type and severity of adverse reactions in children were essentia<strong>l </strong>y&nbsp; similar&nbsp; to&nbsp; those&nbsp; in adults.</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting&nbsp; suspected &nbsp;adverse&nbsp; reactions after authorisation of the medicinal product is important. It a<strong>l </strong>ows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; Saudi Arabia<em>:</em></p><p><strong><em>&nbsp;</em></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:84.4pt;margin-top:11.05pt;width:383.25pt;height:92.25pt;
  z-index:-251655168;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-left:5.2pt;line-height:12.35pt;
     mso-line-height-rule:exactly'>The National Pharmacovigilance and Drug
     Safety Centre (NPC)<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.1in;margin-right:0in;margin-bottom:
     0in;margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l1 level1 lfo1;tab-stops:14.25pt'><![if !supportLists]><span
     style='letter-spacing:-.75pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>SFDA Ca<b style='mso-bidi-font-weight:normal'>l </b><span
     style='letter-spacing:-.2pt'>Center:</span><span style='letter-spacing:
     1.8pt'> </span>19999<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.35pt;margin-right:0in;margin-bottom:
     0in;margin-left:0in;margin-bottom:.0001pt'><span style='font-size:10.5pt;
     mso-bidi-font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoBodyText style='margin-left:14.2pt;text-indent:-9.05pt;
     mso-list:l1 level1 lfo1;tab-stops:14.25pt'><![if !supportLists]><span
     style='letter-spacing:-.75pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><a href="mailto:npc.drug@sfda.gov.sa"><span
     style='color:windowtext;letter-spacing:-.15pt;text-decoration:none;
     text-underline:none'>E-mail:npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:0in'><span style='font-size:11.5pt;
     mso-bidi-font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoBodyText style='margin-left:17.2pt;text-indent:-12.05pt;
     mso-list:l1 level1 lfo1;tab-stops:17.25pt'><![if !supportLists]><span
     style='letter-spacing:-.75pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span style='letter-spacing:-.15pt'>Website:https://ade.sfda.gov.sa/</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="515" height="127" alt="Text Box: The National Pharmacovigilance and Drug Safety Centre (NPC)
o	SFDA Cal Center: 19999

o	E-mail:npc.drug@sfda.gov.sa

o	Website:https://ade.sfda.gov.sa/
" src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p><strong>o Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Headache and&nbsp; dizziness&nbsp; have&nbsp; been&nbsp; reported&nbsp; after&nbsp; the&nbsp; administration&nbsp; of&nbsp;&nbsp; sapropterin dihydrochloride&nbsp; above the recommended maximum dose of 20 mg/kg/day. Treatment &nbsp;of overdose should be directed to symptoms. A shortening of the QT interval (-8.32 msec) was observed in a study with a single supra-therapeutic dose of 100 mg/kg (5 times the maximum recommended dose); this should be taken into consideration in managing patients who have a pre-existing shortened QT interval (e.g. patients with familial short QT syndrome).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other alimentary tract and&nbsp; metabolism&nbsp; products,&nbsp; Various&nbsp; alimentary tract and metabolism products, ATC code: A16AX07</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Hyperphenylalaninaemia&nbsp; (HPA)&nbsp; is&nbsp; diagnosed as&nbsp; an&nbsp; abnormal&nbsp; elevation&nbsp; in&nbsp; blood&nbsp; phenylalanine levels and is usua<strong>l </strong>y caused by autosomal&nbsp; recessive&nbsp; mutations&nbsp; in&nbsp; the&nbsp; genes&nbsp; encoding&nbsp; for phenylalanine hydroxylase enzyme (in the case of phenylketonuria, PKU) or for the enzymes involved in 6R-tetrahydrobiopterin (6R-BH4) biosynthesis or regeneration (in the case of BH4 deficiency). BH4 deficiency is a&nbsp; group of&nbsp; disorders&nbsp; arising&nbsp; from&nbsp; mutations&nbsp; or&nbsp; deletions&nbsp; in&nbsp; the genes encoding for one of the five enzymes involved in the biosynthesis or recycling of BH4. In</p><p>&nbsp;</p><p>&nbsp;</p><p>both&nbsp; cases,&nbsp; phenylalanine&nbsp; cannot&nbsp; be&nbsp; effectively&nbsp; transformed&nbsp; into&nbsp; the&nbsp; amino&nbsp; acid&nbsp; tyrosine,&nbsp; leading to increased phenylalanine levels in the blood.</p><p>Sapropterin is a synthetic version of the natura<strong>l </strong>y occurring 6R-BH4, which is a cofactor of the hydroxylases for phenylalanine, tyrosine and tryptophan.</p><p>The rationale for administration of Sapropterin dihydrochloride in patients with BH4-responsive PKU&nbsp; is&nbsp; to&nbsp; enhance&nbsp; the&nbsp; activity&nbsp; of&nbsp; the&nbsp; defective&nbsp; phenylalanine&nbsp;&nbsp; hydroxylase&nbsp; and&nbsp; thereby&nbsp; increase or restore the oxidative metabolism of phenylalanine sufficient to reduce or maintain blood phenylalanine levels, prevent&nbsp; or&nbsp; decrease&nbsp; further&nbsp; phenylalanine&nbsp; accumulation,&nbsp;&nbsp; and&nbsp;&nbsp; increase tolerance to phenylalanine intake in the diet. The rationale for administration of Sapropterin dihydrochloride&nbsp; in&nbsp; patients with&nbsp; BH4 Deficiency&nbsp; is&nbsp; to &nbsp;replace&nbsp; the&nbsp; deficient&nbsp; levels&nbsp; of&nbsp;&nbsp; BH4, thereby restoring the activity of phenylalanine hydroxylase.</p><p><u>Clinical efficacy</u></p><p>&nbsp;</p><p>The Phase III clinical development program &nbsp;for sapropterin dihydrochloride included 2, randomised placebo-contro<strong>l </strong>ed studies in patients with PKU.&nbsp; The&nbsp; results&nbsp; of&nbsp; these&nbsp; studies demonstrate the&nbsp; efficacy&nbsp; of&nbsp; sapropterin&nbsp; dihydrochloride&nbsp; to&nbsp; reduce&nbsp; blood&nbsp; phenylalanine&nbsp; levels&nbsp; and to increase dietary phenylalanine tolerance.</p><p>In 88 subjects with poorly controlled PKU&nbsp; who&nbsp; had&nbsp; elevated&nbsp; blood&nbsp; phenylalanine&nbsp; levels&nbsp; at screening, sapropterin&nbsp; dihydrochloride&nbsp; 10&nbsp; mg/kg/day&nbsp; significantly&nbsp; reduced&nbsp;&nbsp; blood&nbsp; phenylalanine levels as compared to placebo. The baseline blood phenylalanine levels for the sapropterin dihydrochloride-treated group and the&nbsp; placebo &nbsp;group were &nbsp;similar,&nbsp; with&nbsp; mean&nbsp; &plusmn;&nbsp; SD&nbsp; baseline blood phenylalanine levels of 843 &plusmn; 300&nbsp; &mu;mol/l and&nbsp; 888&nbsp; &plusmn;&nbsp; 323&nbsp; &mu;mol/l,&nbsp; respectively.&nbsp; The&nbsp; mean &plusmn; SD decrease from baseline in blood phenylalanine levels at&nbsp; the&nbsp; end&nbsp; of&nbsp; the&nbsp; 6&nbsp; week&nbsp; study&nbsp; period was 236 &plusmn; 257 &mu;mol/l for the sapropterin treated group (n=41) as compared to an increase of 2.9</p><p>&plusmn; 240 &mu;mol/l for the placebo&nbsp; group (n=47) (p&lt;0.001). For patients with baseline blood phenylalanine levels &ge;600 &mu;mol/l, 41.9% (13/31) of those&nbsp; treated &nbsp;with&nbsp; sapropterin&nbsp; and&nbsp; 13.2% (5/38) of those treated with placebo&nbsp; had&nbsp; blood&nbsp; phenylalanine&nbsp; levels&nbsp; &lt;&nbsp; 600&nbsp; &mu;mol/l&nbsp; at&nbsp; the&nbsp; end&nbsp; of the 6-week study period (p=0.012).</p><p>&nbsp;</p><p>&nbsp;</p><p>In a&nbsp; separate&nbsp; 10-week,&nbsp; placebo-controlled&nbsp; study,&nbsp; 45&nbsp; PKU&nbsp; patients&nbsp; with&nbsp; blood&nbsp; phenylalanine levels contro<strong>l </strong>ed on a stable phenylalanine-restricted diet (blood phenylalanine &le;480 &mu;mol/l on enrolment) were randomised 3:1 to &nbsp;treatment with&nbsp; sapropterin&nbsp; dihydrochloride&nbsp; 20&nbsp; mg/kg/day (n=33) or placebo (n=12). After 3-weeks of treatment with sapropterin dihydrochloride 20 mg/kg/day, blood phenylalanine levels were significantly reduced; the mean &plusmn; SD decrease from baseline in blood phenylalanine level within this group was 149 &plusmn; 134 &mu;mol/l (p&lt;0.001). After&nbsp; 3&nbsp; weeks, subjects in both the sapropterin and placebo treatment groups were continued on their phenylalanine-restricted diets and dietary phenylalanine intake was increased or decreased using standardised phenylalanine supplements with a goal to maintain blood phenylalanine levels at</p><p>&lt;360&nbsp; &mu;mol/l.&nbsp; There was a significant difference in dietary&nbsp; phenylalanine tolerance in the sapropterin treatment group as compared to the placebo group. The mean &plusmn; SD increase in dietary phenylalanine tolerance was 17.5 &plusmn; 13.3 mg/kg/day for the group treated with sapropterin dihydrochloride 20 mg/kg/day, compared to 3.3 &plusmn; 5.3 mg/kg/day for the placebo &nbsp;group (p=0.006). For the sapropterin treatment group,&nbsp; the&nbsp; mean&nbsp; &plusmn;&nbsp; SD&nbsp; total&nbsp; dietary&nbsp; phenylalanine tolerance was 38.4 &plusmn; 21.6 mg/kg/day during treatment with sapropterin dihydrochloride 20 mg/kg/day compared to 15.7 &plusmn; 7.2 mg/kg/day before treatment</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The&nbsp; safety,&nbsp; efficacy&nbsp; and&nbsp; population&nbsp;&nbsp; pharmacokinetics&nbsp;&nbsp; of&nbsp;&nbsp; sapropterin&nbsp;&nbsp; dihydrochloride&nbsp;&nbsp; in paediatric patients aged &lt;7 years were studied in two open-label studies.</p><p>The first study&nbsp; was&nbsp; a&nbsp; multicentre,&nbsp; open-label,&nbsp; randomised,&nbsp; controlled&nbsp; study&nbsp; in&nbsp; children&nbsp; &lt;4&nbsp; years old with a confirmed diagnosis of PKU. 56 paediatric PKU patients &lt;4&nbsp; years&nbsp; of&nbsp; age&nbsp; were randomised 1:1 to receive either 10 mg/kg/day sapropterin dihydrochloride in conjunction with a phenylalanine-restricted diet (n=27),&nbsp; or&nbsp; just a&nbsp; phenylalanine-restricted&nbsp; diet&nbsp; (n=29)&nbsp;&nbsp; over&nbsp; a&nbsp; 26- week Study Period.</p><p>It was intended that a<strong>l </strong>patients maintained blood phenylalanine levels within&nbsp; a&nbsp; range&nbsp; of&nbsp; 120-360 &mu;mol/l (defined as &ge;120 to &lt;360 &mu;mol/l) through monitored dietary intake during the 26-week Study Period. If after approximately 4 weeks, a patient&#39;s phenylalanine tolerance had&nbsp; not&nbsp; increased by &gt;20% <em>versus </em>baseline,&nbsp; the&nbsp; sapropterin&nbsp; dihydrochloride&nbsp; dose&nbsp; was&nbsp; increased&nbsp; in&nbsp; a&nbsp; single step to 20 mg/kg/day.</p><p>&nbsp;</p><p>&nbsp;</p><p>The results of this study demonstrated that daily dosing with 10 or 20 mg/kg/day of sapropterin dihydrochloride in conjunction with a phenylalanine-restricted diet led to&nbsp; statistica<strong>l </strong>y significant improvements in dietary&nbsp; phenylalanine tolerance compared with dietary phenylalanine restriction alone&nbsp; while&nbsp; maintaining&nbsp; blood&nbsp; phenylalanine&nbsp; levels&nbsp; within&nbsp; the&nbsp; target&nbsp; range&nbsp;&nbsp; (&ge;120&nbsp;&nbsp; to&nbsp;&nbsp; &lt;360&nbsp; &mu;mol/l). The adjusted mean dietary phenylalanine tolerance in the sapropterin dihydrochloride in conjunction with a phenylalanine-restricted diet group was 80.6 mg/kg/day and was statistica<strong>l </strong>y significantly greater (p&lt;0.001) than the adjusted mean dietary phenylalanine tolerance in dietary phenylalanine therapy alone&nbsp; group (50.1&nbsp; mg/kg/day).&nbsp; In&nbsp; the&nbsp; clinical&nbsp;&nbsp; trial&nbsp;&nbsp; extension&nbsp;&nbsp; period, patients maintained &nbsp;dietary&nbsp; phenylalanine&nbsp;&nbsp; tolerance&nbsp;&nbsp; while&nbsp;&nbsp; on&nbsp;&nbsp; sapropterin&nbsp;&nbsp; dihydrochloride treatment in&nbsp; conjunction&nbsp; with&nbsp; a&nbsp; Phe-restricted&nbsp; diet,&nbsp; demonstrating&nbsp; sustained&nbsp; benefit&nbsp; over&nbsp;&nbsp; 3.5 years.</p><p>The second study was a multicenter, uncontro<strong>l </strong>ed, open-label study designed to &nbsp;evaluate the safety and effect on preservation of neurocognitive function of sapropterin dihydrochloride 20 mg/kg/day in combination with a phenylalanine-restricted&nbsp; diet&nbsp; in&nbsp; children&nbsp; with&nbsp; PKU&nbsp; less&nbsp; than&nbsp; 7 years of age at study entry. Part 1 of the study (4&nbsp; weeks)&nbsp; assessed&nbsp; patients&#39;&nbsp; response&nbsp;&nbsp; to&nbsp;&nbsp; sapropterin dihydrochloride; Part 2 of the study (up to&nbsp; 7&nbsp; years&nbsp; of&nbsp; follow-up)&nbsp; evaluated neurocognitive&nbsp; function&nbsp; with&nbsp; age-appropriate measures, and monitored &nbsp;long-term &nbsp;safety &nbsp;in patients responsive to sapropterin dihydrochloride. Patients with pre-existing neurocognitive impairment (IQ &lt;80) were&nbsp; excluded&nbsp; from the study. Ninety-three patients were&nbsp; enro<strong>l </strong>ed&nbsp; into&nbsp; Part 1, and 65 patients were enrolled&nbsp; into&nbsp; Part 2, of whom 49 (75%) patients&nbsp; completed&nbsp; the&nbsp; study with 27 (42%) patients providing Fu<strong>l </strong>Scale IQ (FSIQ) data at year 7.</p><p>Mean Indices of Dietary Control were maintained between 133 &mu;mol/L and 375 &mu;mol/L blood phenylalanine for a<strong>l </strong>age groups at&nbsp; a<strong>l&nbsp; </strong>time&nbsp; points.&nbsp; At&nbsp; baseline,&nbsp; mean&nbsp; Bayley-III&nbsp; score&nbsp; (102, SD=9.1, n=27), WPPSI-III score (101, SD=11, n=34) and WISC-IV score (113, SD=9.8, n=4)</p><p>were within the average range for the normative population.</p><p>&nbsp;</p><p>Among 62 patients with a minimum of two FSIQ assessments, the 95% lower limit confidence interval of the mean change over an average 2-year period was -1.6 points, within the clinica<strong>l </strong>y expected variation of &plusmn;5 points. No additional adverse reactions were identified with long-term use of sapropterin dihydrochloride in children less than 7 years of age.</p><p>&nbsp;</p><p>&nbsp;</p><p>Limited studies have been conducted in patients under 4 years of age with BH4&nbsp; deficiency&nbsp; using another formulation of the same active substance (sapropterin) or an&nbsp; un-registered&nbsp; preparation&nbsp; of BH4.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>Sapropterin is absorbed after oral administration of the dissolved tablet, and the maximum blood concentration (Cmax ) is achieved 3&nbsp; to&nbsp; 4&nbsp; hours&nbsp; after&nbsp; dosing in the&nbsp; fasted&nbsp; state. The&nbsp; rate and&nbsp; extent of absorption of sapropterin is influenced by food. The absorption of sapropterin is higher after a high-fat, high-calorie meal as compared to &nbsp;fasting,&nbsp; resulting,&nbsp; in&nbsp; average,&nbsp; in&nbsp; 40-85%&nbsp; higher&nbsp; maximum blood concentrations achieved 4 to 5 hours after administration.</p><p>Absolute bioavailability or bioavailability for humans after oral administration is not known. <u>Distribution</u></p><p>In non-clinical studies, sapropterin was primarily distributed to &nbsp;the kidneys, adrenal glands, and liver as assessed by levels of total&nbsp; and reduced&nbsp; biopterin concentrations. In rats, &nbsp;fo<strong>l </strong>owing intravenous&nbsp; radiolabeled sapropterin&nbsp; administration,&nbsp; radioactivity&nbsp; was &nbsp;found&nbsp; to distribute in foetuses. Excretion of total biopterin in milk was demonstrated in rats by intravenous&nbsp; route.&nbsp; No increase in total biopterin concentrations in either foetuses or milk was observed in rats after oral administration of 10&nbsp; mg/kg sapropterin dihydrochloride.</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Sapropterin dihydrochloride is primarily metabolised in the &nbsp;liver &nbsp;to &nbsp;dihydrobiopterin &nbsp;and biopterin. Since sapropterin dihydrochloride is a synthetic version&nbsp; of&nbsp; the&nbsp; natura<strong>l </strong>y&nbsp; occurring&nbsp; 6R- BH4, it can be reasonably anticipated to&nbsp; undergo the same metabolism, including&nbsp; 6R-BH4 regeneration.</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Fo<strong>l </strong>owing&nbsp; intravenous&nbsp; administration&nbsp; in&nbsp; rats, &nbsp;sapropterin&nbsp; dihydrochloride&nbsp; is&nbsp;&nbsp; mainly&nbsp;&nbsp; excreted&nbsp;&nbsp; in the urine. Following oral administration&nbsp; it&nbsp; is&nbsp; mainly&nbsp; eliminated&nbsp; through&nbsp; faeces&nbsp; while&nbsp; a&nbsp; sma<strong>l </strong>proportion is excreted in urine.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Population pharmacokinetics</u></p><p>&nbsp;</p><p>Population pharmacokinetic&nbsp; analysis&nbsp; of&nbsp; sapropterin&nbsp; including&nbsp; patients&nbsp; from&nbsp; birth&nbsp; to&nbsp; 49&nbsp; years&nbsp; of age showed that body weight is the only covariate substantia<strong>l </strong>y affecting clearance or volume of distribution.</p><p><u>Drug interactions</u></p><p>&nbsp;</p><p><em>In vitro </em>studies</p><p>&nbsp;</p><p><em>In vitro, </em>sapropterin did not inhibit&nbsp; CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4/5, nor induce CYP1A2, 2B6, or 3A4/5.</p><p>Based on an <em>in vitro </em>study, there is potential for sapropterin dihydrochloride to &nbsp;inhibit p- glycoprotein (P-gp) and breast cancer resistance&nbsp; protein&nbsp; (BCRP)&nbsp; in&nbsp; the&nbsp; gut&nbsp; at&nbsp; the&nbsp; therapeutic doses. A&nbsp; higher intestinal concentration of Sapropterin &nbsp;dihydrochloride is needed &nbsp;to &nbsp;inhibit BCRP than P-gp, as inhibitory potency in intestine for BCRP (IC50=267 &mu;M) is lower than P-gp (IC50=158 &mu;M).</p><p><em>In vivo </em>studies</p><p>&nbsp;</p><p>In healthy subjects, administration&nbsp; of&nbsp; a&nbsp; single&nbsp; dose&nbsp; of&nbsp; Sapropterin&nbsp;&nbsp; dihydrochloride&nbsp; at&nbsp; the maximum therapeutic dose of&nbsp; 20&nbsp; mg/kg&nbsp; had&nbsp; no&nbsp; effect&nbsp; on&nbsp; the&nbsp; pharmacokinetics&nbsp; of&nbsp; a&nbsp; single&nbsp; dose of digoxin (P-gp substrate) administered concomitantly. Based on the <em>in vitro </em>and <em>in vivo </em>results, co-administration of&nbsp; Sapropterin &nbsp;dihydrochloride&nbsp; is&nbsp; unlikely&nbsp; to &nbsp;increase systemic&nbsp; exposure&nbsp; to drugs that are substrates for BCRP.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology (CNS, respiratory, cardiovascular, genitourinary), and toxicity to reproduction.</p><p>An increased&nbsp; incidence&nbsp; of&nbsp; altered&nbsp; renal&nbsp; microscopic&nbsp; morphology&nbsp; (co<strong>l </strong>ecting&nbsp; tubule&nbsp; basophilia)&nbsp; was observed in rats following chronic oral administration of sapropterin dihydrochloride at exposures at or slightly above the maximal recommended human dose.</p><p>&nbsp;</p><p>&nbsp;</p><p>Sapropterin was found to be weakly mutagenic in bacterial ce<strong>l </strong>s and an increase in chromosome aberrations was detected in Chinese hamster lung and ovary ce<strong>l </strong>s.&nbsp; However,&nbsp; sapropterin&nbsp; has&nbsp; not been shown to be genotoxic in the <em>in vitro </em>test with human lymphocytes as we<strong>l </strong>as in <em>in vivo </em>micronucleus mouse tests.</p><p>No tumorigenic activity was observed in an oral&nbsp; carcinogenicity&nbsp; study&nbsp; in&nbsp; mice&nbsp; at&nbsp; doses&nbsp; of up&nbsp; to 250 mg/kg/day (12.5 to 50 times the human therapeutic dose range).</p><p>Emesis has been observed&nbsp; in&nbsp; both&nbsp; the&nbsp; safety&nbsp; pharmacology&nbsp; and&nbsp; the&nbsp; repeated-dose&nbsp; toxicity&nbsp; studies. Emesis is considered to be related to the pH of the solution containing sapropterin.</p><p>No clear evidence of teratogenic activity was found in rats &nbsp;and in rabbits&nbsp; at&nbsp; doses&nbsp; of&nbsp; approximately 3 and 10 times the maximum&nbsp; recommended&nbsp; human&nbsp; dose,&nbsp; based&nbsp; on&nbsp; body&nbsp; surface area</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sapropterin dihydrochloride 100 mg Tablets</p><p>Mannitol&nbsp;&nbsp; (Pearlitol&nbsp;&nbsp; 160C),&nbsp;&nbsp; Ascorbic acid, &nbsp;Crospovidone&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Ko<strong>l </strong>idon CL), Riboflavin, Co<strong>l </strong>oidal Silicon Dioxide (Aerosil 200), Sodium Stearyl Fumarate, Mannitol (Pearlitol SD 200).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>30&rsquo;s Count HDPE Container</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>na</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company, Aljameah Street,  Malaz  quarter, Riyadh 11441, Saudi Arabia
Tel: +966 11 477 2215
 

Manufacture:
Annora Pharma Private Limited, India

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November-2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>